# EDGAR Filing Document

**Accession Number:** 0001831097
**File Stem:** 0001628280-25-048839
**Filing Date:** 2025-11
**Character Count:** 186449
**Document Hash:** e5807048dfb722c2d205a63beaf08230
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-048839.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001628280-25-048839

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 78

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** agilon health, inc.
- **CENTRAL INDEX KEY:** 0001831097
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 371915147
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40332
- **FILM NUMBER:** 251449185

**BUSINESS ADDRESS:**
- **STREET 1:** 440 POLARIS PARKWAY
- **STREET 2:** SUITE 550
- **CITY:** WESTERVILLE
- **STATE:** OH
- **ZIP:** 43082
- **BUSINESS PHONE:** 562-256-3800

**MAIL ADDRESS:**
- **STREET 1:** 440 POLARIS PARKWAY
- **STREET 2:** SUITE 550
- **CITY:** WESTERVILLE
- **STATE:** OH
- **ZIP:** 43082

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Agilon Health Topco, Inc.
- **DATE OF NAME CHANGE:** 20201103

?xml version='1.0' encoding='ASCII'? agl-20250930

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_______________________________________________________

**FORM 10-Q**

_______________________________________________________

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

**For the quarterly period ended September 30, 2025** 

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**Commission file number 001-40332** 

_______________________________________________________

**agilon health, inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **37-1915147** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**440 Polaris Parkway, Suite 550**

**Westerville, Ohio 43082**

(Address of principal executive offices)

**(562) 256-3800**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common stock, $0.01 par value | AGL | New York Stock Exchange |

---

_______________________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ NO □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer | ⌧ | Accelerated Filer | □ |
| Non-accelerated Filer | □ | Smaller Reporting Company | □ |
| | | Emerging Growth Company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES □ NO ⌧

At October 30, 2025, there were 414,581,604 shares of the registrant's $0.01 par value common stock outstanding.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**agilon health, inc.**

**INDEX**

---

| | | |
|:---|:---|:---|
| **[PART I. FINANCIAL INFORMATION](#if88d396afebb4b2997c2af615b3db7dc_10)** | **[PART I. FINANCIAL INFORMATION](#if88d396afebb4b2997c2af615b3db7dc_10)** | |
| [Item 1.](#if88d396afebb4b2997c2af615b3db7dc_13) | [Financial Statements](#if88d396afebb4b2997c2af615b3db7dc_13): |  |
|  | <u>[Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024](#if88d396afebb4b2997c2af615b3db7dc_16)</u> | [3](#if88d396afebb4b2997c2af615b3db7dc_16) |
|  | <u>[Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024](#if88d396afebb4b2997c2af615b3db7dc_19)</u> | [4](#if88d396afebb4b2997c2af615b3db7dc_19) |
|  | <u>[Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2025 and 2024](#if88d396afebb4b2997c2af615b3db7dc_22)</u> | [5](#if88d396afebb4b2997c2af615b3db7dc_22) |
|  | <u>[Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the Three and Nine Months Ended September 30, 2025 and 2024](#if88d396afebb4b2997c2af615b3db7dc_25)</u> | [6](#if88d396afebb4b2997c2af615b3db7dc_25) |
|  | <u>[Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024](#if88d396afebb4b2997c2af615b3db7dc_28)</u> | [8](#if88d396afebb4b2997c2af615b3db7dc_28) |
|  | <u>[Notes to the Condensed Consolidated Financial Statements](#if88d396afebb4b2997c2af615b3db7dc_31)</u> | [9](#if88d396afebb4b2997c2af615b3db7dc_31) |
| [Item 2.](#if88d396afebb4b2997c2af615b3db7dc_79) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#if88d396afebb4b2997c2af615b3db7dc_79)</u> | [23](#if88d396afebb4b2997c2af615b3db7dc_79) |
| [Item 3.](#if88d396afebb4b2997c2af615b3db7dc_109) | <u>[Quantitative and Qualitative Disclosures About Market Risk](#if88d396afebb4b2997c2af615b3db7dc_109)</u> | [39](#if88d396afebb4b2997c2af615b3db7dc_109) |
| [Item 4.](#if88d396afebb4b2997c2af615b3db7dc_112) | <u>[Controls and Procedures](#if88d396afebb4b2997c2af615b3db7dc_112)</u> | [39](#if88d396afebb4b2997c2af615b3db7dc_112) |
| **[PART II. OTHER INFORMATION](#if88d396afebb4b2997c2af615b3db7dc_115)** | **[PART II. OTHER INFORMATION](#if88d396afebb4b2997c2af615b3db7dc_115)** |  |
| [Item 1.](#if88d396afebb4b2997c2af615b3db7dc_118) | <u>[Legal Proceedings](#if88d396afebb4b2997c2af615b3db7dc_118)</u> | [40](#if88d396afebb4b2997c2af615b3db7dc_118) |
| [Item 1A.](#if88d396afebb4b2997c2af615b3db7dc_121) | <u>[Risk Factors](#if88d396afebb4b2997c2af615b3db7dc_121)</u> | [40](#if88d396afebb4b2997c2af615b3db7dc_121) |
| [Item 5.](#if88d396afebb4b2997c2af615b3db7dc_127) | <u>[Other Information](#if88d396afebb4b2997c2af615b3db7dc_127)</u> | [40](#if88d396afebb4b2997c2af615b3db7dc_127) |
| [Item 6.](#if88d396afebb4b2997c2af615b3db7dc_130) | <u>[Exhibits](#if88d396afebb4b2997c2af615b3db7dc_130)</u> | [41](#if88d396afebb4b2997c2af615b3db7dc_130) |
| <u>[Signatures](#if88d396afebb4b2997c2af615b3db7dc_133)</u> | <u>[Signatures](#if88d396afebb4b2997c2af615b3db7dc_133)</u> | [42](#if88d396afebb4b2997c2af615b3db7dc_133) |

---

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**agilon health, inc.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands, except per share data)

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| | **(unaudited)** | |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $171684 | $188231 |
| &nbsp;&nbsp;&nbsp;Restricted cash and equivalents |  | 5629 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 139170 | 211737 |
| &nbsp;&nbsp;&nbsp;Receivables, net | 947157 | 1017040 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets, net | 80017 | 35137 |
| Total current assets | 1338028 | 1457774 |
| Property and equipment, net | 26148 | 28169 |
| Intangible assets, net | 75254 | 72771 |
| Goodwill | 24133 | 24133 |
| Other assets | 132682 | 151136 |
| &nbsp;&nbsp;&nbsp;Total assets | $1596245 | $1733983 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Medical claims and related payables | $1059398 | $931664 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 145517 | 220342 |
| &nbsp;&nbsp;&nbsp;Current debt | 34966 |  |
| Total current liabilities | 1239881 | 1152006 |
| Long-term debt |  | 34904 |
| Other liabilities | 50287 | 76121 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 1290168 | 1263031 |
| Commitments and contingencies |  |  |
| Stockholders' equity (deficit): |  |  |
| Common stock, $0.01 par value: 2,000,000 shares authorized; 414,570 and 412,194 shares issued and outstanding, respectively | 4146 | 4122 |
| Additional paid-in capital | 2090493 | 2053895 |
| Accumulated deficit | (1789442) | (1586977) |
| Accumulated other comprehensive income (loss) | 880 | (88) |
| &nbsp;&nbsp;&nbsp;Total stockholders' equity (deficit) | 306077 | 470952 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity (deficit) | $1596245 | $1733983 |

---

The condensed consolidated balance sheets include assets and liabilities of consolidated variable interest entities ("VIEs") as agilon health, inc., together with its consolidated subsidiaries and VIEs (the "Company"), is the primary beneficiary of these VIEs. The condensed consolidated balance sheets include total assets that can only be used to settle obligations of the Company's consolidated VIEs totaling $1.10 billion and $1.17 billion as of September 30, 2025 and December 31, 2024, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $1.19 billion and $1.13 billion as of September 30, 2025 and December 31, 2024, respectively. See Note 14 for additional details.

See accompanying Notes to the Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**agilon health, inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(in thousands, except per share data)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Revenues:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical services revenue | $1432437 | $1447697 | $4354355 | $4528471 |
| &nbsp;&nbsp;&nbsp;Other operating revenue | 2884 | 3235 | 8730 | 9573 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 1435321 | 1450932 | 4363085 | 4538044 |
| **Expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical services expense | 1489479 | 1505950 | 4336591 | 4323852 |
| &nbsp;&nbsp;&nbsp;Other medical expenses | 13488 | 9149 | 95845 | 171096 |
| &nbsp;&nbsp;&nbsp;General and administrative | 56198 | 63123 | 178435 | 209157 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 7430 | 6218 | 21625 | 17969 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 1566595 | 1584440 | 4632496 | 4722074 |
| **Income (loss) from operations** | (131274) | (133508) | (269411) | (184030) |
| **Other income (expense):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from equity method investments | 13133 | 2047 | 31217 | 17686 |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 9441 | 16061 | 26581 | 26794 |
| &nbsp;&nbsp;&nbsp;Interest expense | (1838) | (1622) | (4925) | (4603) |
| **Income (loss) before income taxes** | (110538) | (117022) | (216538) | (144153) |
| &nbsp;&nbsp;&nbsp;Income tax benefit (expense) | 331 | 590 | 73 | 306 |
| **Income (loss) from continuing operations** | (110207) | (116432) | (216465) | (143847) |
| **Discontinued operations:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) before gain (loss) on sales |  | (1183) |  | (1701) |
| &nbsp;&nbsp;&nbsp;Adjustments on sale of assets, net |  |  | 14000 | (8763) |
| **Total discontinued operations** |  | (1183) | 14000 | (10464) |
| **Net income (loss)** | (110207) | (117615) | (202465) | (154311) |
| &nbsp;&nbsp;Noncontrolling interests' share in (earnings) loss |  |  |  | (50) |
| **Net income (loss) attributable to common shares** | $(110207) | $(117615) | $(202465) | $(154361) |
| **Net income (loss) per common share, basic and diluted** |  |  |  |  |
| Continuing operations | $(0.27) | $(0.29) | $(0.52) | $(0.35) |
| Discontinued operations | $— | $— | $0.03 | $(0.03) |
| **Weighted average shares outstanding** |  |  |  |  |
| Basic and diluted | 414465 | 411591 | 413751 | 410604 |

---

See accompanying Notes to the Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**agilon health, inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

(in thousands)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $(110207) | $(117615) | $(202465) | $(154311) |
| Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net unrealized gain (loss) on marketable securities, net of tax | 89 | 2736 | 911 | 2604 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 4 | 12 | 57 | (5) |
| Total comprehensive income (loss) | (110114) | (114867) | (201497) | (151712) |
| Comprehensive (income) loss attributable to noncontrolling interests |  |  |  | (50) |
| Total comprehensive income (loss) attributable to agilon health, inc. | $(110114) | $(114867) | $(201497) | $(151762) |

---

See accompanying Notes to the Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**agilon health, inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)**

(in thousands)

(unaudited)

For the three months ended September 30, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** |
| | **Common Stock** | **Common Stock** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br> Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Total <br>Stockholders' <br>Equity <br>(Deficit)** |
| | **Shares** | **Amount** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br> Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Total <br>Stockholders' <br>Equity <br>(Deficit)** |
| **July 1, 2025** | 414283 | $4143 | $2083234 | $(1679235) | $787 | $408929 |
| Net income (loss) |  |  |  | (110207) |  | (110207) |
| Other comprehensive income (loss) |  |  |  |  | 93 | 93 |
| Vesting of restricted stock units | 417 | 4 | (4) |  |  |  |
| Shares withheld related to net share settlement | (130) | (1) | (235) |  |  | (236) |
| Stock-based compensation expense |  |  | 7498 |  |  | 7498 |
| **September 30, 2025** | 414570 | $4146 | $2090493 | $(1789442) | $880 | $306077 |

---

For the three months ended September 30, 2024:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** |
| | **Common Stock** | **Common Stock** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br>Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Noncontrolling <br>Interests** | **Total <br>Stockholders' <br>Equity<br>(Deficit)** |
| | **Shares** | **Amount** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br>Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Noncontrolling <br>Interests** | **Total <br>Stockholders' <br>Equity<br>(Deficit)** |
| **July 1, 2024** | 411447 | $4114 | $2038540 | $(1363572) | $(2447) | $(768) | $675867 |
| Net income (loss) |  |  |  | (117615) |  |  | (117615) |
| Other comprehensive income (loss) |  |  |  |  | 2748 |  | 2748 |
| Exercise of stock options | 32 |  | 132 |  |  |  | 132 |
| Vesting of restricted stock units | 549 | 7 | (7) |  |  |  |  |
| Shares withheld related to net share settlement | (68) | (1) | (286) |  |  |  | (287) |
| Stock-based compensation expense |  |  | 13259 |  |  |  | 13259 |
| Dissolution of partially owned entity |  |  |  |  |  | 768 | 768 |
| **September 30, 2024** | 411960 | $4120 | $2051638 | $(1481187) | $301 | $— | $574872 |

---

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**agilon health, inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)**

(in thousands)

(unaudited)

For the nine months ended September 30, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** |
| | **Common Stock** | **Common Stock** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br> Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Total <br>Stockholders' <br>Equity <br>(Deficit)** |
| | **Shares** | **Amount** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br> Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Total <br>Stockholders' <br>Equity <br>(Deficit)** |
| **January 1, 2025** | 412194 | $4122 | $2053895 | $(1586977) | $(88) | $470952 |
| Net income (loss) |  |  |  | (202465) |  | (202465) |
| Other comprehensive income (loss) |  |  |  |  | 968 | 968 |
| Exercise of stock options | 24 |  | 110 |  |  | 110 |
| Vesting of restricted stock units | 3021 | 30 | (30) |  |  |  |
| Shares withheld related to net share settlement | (669) | (6) | (3081) |  |  | (3087) |
| Stock-based compensation expense |  |  | 39599 |  |  | 39599 |
| **September 30, 2025** | 414570 | $4146 | $2090493 | $(1789442) | $880 | $306077 |

---

For the nine months ended September 30, 2024:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** | **Total Stockholders' Equity (Deficit)** |
| | **Common Stock** | **Common Stock** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br> Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Noncontrolling <br> Interest** | **Total <br>Stockholders' <br>Equity <br>(Deficit)** |
| | **Shares** | **Amount** | **Additional <br>Paid-In <br>Capital** | **Accumulated <br> Deficit** | **Accumulated Other Comprehensive <br>Income (Loss)** | **Noncontrolling <br> Interest** | **Total <br>Stockholders' <br>Equity <br>(Deficit)** |
| **January 1, 2024** | 406387 | $4064 | $1986899 | $(1326826) | $(2298) | $(818) | $661021 |
| Net income (loss) |  |  |  | (154361) |  | 50 | (154311) |
| Other comprehensive income (loss) |  |  |  |  | 2599 |  | 2599 |
| Exercise of stock options | 1508 | 15 | 2743 |  |  |  | 2758 |
| Vesting of restricted stock units | 2409 | 24 | (24) |  |  |  |  |
| Shares withheld related to net share settlement | (318) | (3) | (1565) |  |  |  | (1568) |
| Issuance of common stock | 1974 | 20 | 15210 |  |  |  | 15230 |
| Stock-based compensation expense |  |  | 48375 |  |  |  | 48375 |
| Dissolution of partially owned entity |  |  |  |  |  | 768 | 768 |
| **September 30, 2024** | 411960 | $4120 | $2051638 | $(1481187) | $301 | $— | $574872 |

---

See accompanying Notes to the Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**agilon health, inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in thousands)

(unaudited)

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net income (loss) | $(202465) | $(154311) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 21625 | 17969 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 39599 | 48375 |
| &nbsp;&nbsp;&nbsp;Loss (income) from equity method investments | (31217) | (17686) |
| &nbsp;&nbsp;&nbsp;Distributions of earnings from equity method investments |  | 3340 |
| &nbsp;&nbsp;&nbsp;Adjustments on sale of assets, net | (14000) | 3784 |
| &nbsp;&nbsp;&nbsp;Other noncash items | (5571) | (491) |
| Changes in operating assets and liabilities: | 106803 | 24824 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | (85226) | (74196) |
| **Cash flows from investing activities:** |  |  |
| Purchase of property and equipment | (10274) | (9985) |
| Purchase of intangible assets | (23076) | (18877) |
| Investment in loans receivable and other | (1000) | (9742) |
| Investments in marketable securities | (60154) | (12006) |
| Proceeds from maturities of marketable securities and other | 160531 | 166828 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 66027 | 116218 |
| **Cash flows from financing activities:** |  |  |
| Proceeds from (payments for) equity issuances, net | (2977) | 1189 |
| Repayments of long-term debt |  | (3750) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | (2977) | (2561) |
| Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents | (22176) | 39461 |
| **Cash, cash equivalents and restricted cash and equivalents, beginning of period** | 193860 | 114329 |
| **Cash, cash equivalents and restricted cash and equivalents, end of period** | $171684 | $153790 |

---

See accompanying Notes to the Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**agilon health, inc.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

(Unaudited)

**NOTE 1. Business**<br>

*Description of Business*

agilon health, inc., together with its consolidated subsidiaries and VIEs (the "Company"), through its partnerships and platform, provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. As of September 30, 2025, the Company, through its contracted physician networks, provided care to approximately 502,800 Medicare Advantage members enrolled with private health plans. Additionally, the Company participates in the Centers for Medicare & Medicaid Services' ("CMS") Accountable Care Organization Realizing Equity, Access, and Community Health ("ACO REACH") Model and Medicare Shared Savings Program ("MSSP," and together with ACO REACH, the "CMS ACO Models") through its equity method investments.

See Note 14 for additional discussions related to the Company's involvement with VIEs.

The Company's largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC ("CD&R"), a private equity firm. All funds affiliated with CD&R are considered related parties.

**NOTE 2. Summary of Significant Accounting Policies**<br>

*Basis of Presentation*

The accompanying condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The condensed consolidated financial statements include the accounts of agilon health, inc., its wholly-owned subsidiaries, and joint ventures and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments unless otherwise indicated), which the Company considers necessary to present fairly its financial position, results of operations, and cash flows, have been included. Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. The accompanying condensed consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2024 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

*Use of Estimates*

Management is required to make estimates and assumptions in the preparation of financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates can include, among other things, those used to determine revenues and related receivables from risk adjustments, medical services expense and related payables (including the reserve for incurred but not reported ("IBNR") claims), and the valuation and related recognition of impairments of long-lived assets, including goodwill. Management's estimates for revenue recognition, medical services expense, and other estimates, judgments, and assumptions, may be materially and adversely different from actual results. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.

*Property and Equipment*

As of September 30, 2025 and December 31, 2024, the Company's gross carrying amount of property and equipment was $59.0 million and $52.9 million, with accumulated depreciation of $32.9 million and $24.7 million, respectively. For the three months ended September 30, 2025 and 2024, the Company recognized $3.8 million and $3.1 million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

consolidated statements of operations. For the nine months ended September 30, 2025 and 2024, the Company recognized $11.5 million and $8.9 million, respectively, in depreciation expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.

*Income Taxes*

The Company determines the income tax provision for interim periods using an estimate of the Company's annual effective tax rate, applied to year-to-date results, adjusted for discrete items arising in that quarter. In each quarter, the Company updates its estimated annual effective tax rate, and if the estimated annual effective tax rate changes, a cumulative catch-up adjustment is recorded in that quarter. The Company applied the intra-period tax allocation rules to allocate income taxes between continuing operations and discontinued operations as prescribed in U.S. GAAP, where the tax effect of income (loss) before income taxes from continuing operations is computed without regard to the tax effects of income (loss) before income taxes from the other categories.

On July 4, 2025, the "One Big Beautiful Bill Act" was signed into law in the U.S., which contains a broad range of tax reform provisions. The One Big Beautiful Bill Act did not have a material impact to the Company's effective tax rate for the nine months ended September 30, 2025; however, the Company will continue to monitor developments and evaluate any potential future impacts.

*Segment Reporting*

The Company operates a Medicare-centric, capitated line of business and is organized as a single operating and reportable segment based on the manner in which the Company's Chief Operating Decision Maker ("CODM") evaluates performance and makes decisions about how to allocate resources. The Company's CODM is the Office of the Chairman. Segment asset information, which is presented on the consolidated balance sheet, is not used by the CODM to assess performance and make decisions about how to allocate resources. The Company's segment measure of profit or loss is consolidated net income (loss). The CODM uses the segment measure of profit or loss to assess performance and make resource allocation decisions, primarily through periodic budgeting and company performance reviews. Significant expense categories included within the segment measure of profit or loss that are regularly provided to the CODM include medical services expense, other medical expense, and platform support costs. Medical services expense and other medical expense amounts are included in the consolidated statements of operations. Platform support costs were $38.7 million and $42.4 million for the three months ended September 30, 2025 and 2024, respectively. For the three months ended September 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $3.9 million and $11.1 million, respectively. Platform support costs were $120.3 million and $129.8 million for the nine months ended September 30, 2025 and 2024, respectively. For the nine months ended September 30, 2025 and 2024, other segment items, which consists of general and administrative expenses (excluding platform support costs), depreciation and amortization, other income (expense), net, income tax benefit (expense), and results from discontinued operations, were $12.8 million and $67.7 million, respectively.

*Recent Accounting Pronouncements*

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* (*"*ASU 2023-09"), which amends certain disclosure requirements related to income taxes. The amendments in ASU 2023-09 require public business entities on an annual basis to: (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The amendments in ASU 2023-09 can be applied on a prospective basis or retrospective application. Early adoption is permitted. The new guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations, cash flows, or disclosures.

In November 2024, the FASB issued ASU 2024-03, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses* ("ASU 2024-03"). In January 2025, the FASB issued Accounting Standards Update ("ASU") 2025-01, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date* ("ASU 2025-01"). The amendments in ASU 2024-03 require public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items by breaking down certain expense line items into specified natural expense categories, including purchases of inventory, employee compensation, deprecation,

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

intangible asset amortization, and depletion. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The amendments in ASU 2024-03 can be applied on a prospective basis or retrospective basis and early adoption is permitted. The amendments in ASU 2025-01 clarify the effective date of ASU 2024-03 stating that all public business entities are required to adopt the update in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. ASU 2025-01 does not change the effective date of ASU 2024-03 but was issued to provide clarity on the effective date for public business entities that do not have a calendar year-end. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 and ASU 2025-01 on its disclosures.

In September 2025, the FASB issued ASU 2025-06, *Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software* ("ASU 2025-06"). The amendments in ASU 2025-06 modernize the guidance in Subtopic 350-40 to reflect the software development approaches currently used as software is not always developed in a linear manner. To clarify how the guidance applies to both linear and nonlinear software development, the amendments in ASU 2025-06 remove all references to the "development stages" from Subtopic 350-40 and instead requires that software development costs be capitalized when (i) management, with relevant authority, commits to funding a computer software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. The amendments in ASU 2025-06 also provide new guidance on how to evaluate whether the probable-to-complete recognition threshold has been met and specifies that the disclosure requirements in Subtopic 360-10, *Property, Plant, and Equipment—Overall*, are required for all capitalized internal-use software costs. The amendments in ASU 2025-06 are effective for annual reporting periods beginning after December 31, 2027, and interim reporting periods within those annual reporting periods. The amendments in ASU 2025-06 can be applied on a prospective, retrospective, or modified transition approach basis. The new guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations, cash flows, or disclosures.

**NOTE 3. Revenue, Receivables, and Concentration of Credit Risk**<br>

*Medical Services Revenue* 

Medical services revenue consists of capitation fees under contracts with various Medicare Advantage payors ("payors"). Under the typical capitation arrangement, the Company is entitled to monthly per-member, per-month ("PMPM") fees to provide a defined range of healthcare services for Medicare Advantage health plan members ("members") attributed to the Company's contracted primary care physicians. In certain of the Company's payor arrangements, it is also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members. PMPM fees are determined as a percent of the premium payors receive from CMS for these members. The Company generally accepts full financial risk for members attributed to its contracted primary care physicians and therefore is responsible for the cost of all healthcare services required by those members. Fees are generally recorded gross in revenue because the Company is acting as a principal in coordinating and controlling the range of services provided (other than clinical decisions) under its capitation contracts with payors. Capitation contracts with payors are generally multi-year arrangements and have a single performance obligation that constitutes a series, as defined by Accounting Standards Codification ("ASC") 606, *Revenue From Contracts With Customers* ("ASC 606"), to stand ready on a monthly basis to provide all aspects of necessary medical care to members for the contracted period. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term.

The transaction price for the Company's capitation contracts is variable, as the PMPM fees to which the Company is entitled are subject to periodic adjustment under CMS's risk adjustment payment methodology. CMS deploys a risk adjustment model that determines premiums paid to all payors according to each member's health status and certain demographic factors. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from various settings. The Company and healthcare providers collect and submit the necessary and available diagnosis data to payors and such data is utilized by the Company to estimate risk adjustment payments to be received in subsequent periods. Risk adjustment-related revenues are estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. PMPM fees are also subject to adjustment for incentives or penalties based on the achievement of certain quality metrics defined in the Company's contracts with payors. The Company recognizes incentive revenue as earned using the most likely amount methodology and only to the extent that it is probable that a significant reversal of incentive revenue will not occur once any uncertainty is resolved.

Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

*Receivables*

Receivables primarily consist of amounts due under capitation contracts with various payors. Receivables due under capitation contracts are recorded monthly based on reports received from payors and management's estimate of risk adjustment payments to be received in subsequent periods for open performance years. Receivables are recorded at the amount expected to be realized.

*Concentration*

The Company contracts with various payors whereby the Company is entitled to monthly PMPM fees to provide a defined range of healthcare services for members attributed to its contracted primary care physicians. The Company generally accepts full financial risk for such members and therefore is responsible for the cost of all healthcare services required by them. Substantially all of the Company's receivable balances are from a small number of payors. Revenue from Medicare Advantage payors constitutes substantially all of the Company's total revenue for the three and nine months ended September 30, 2025 and 2024.

The following table provides the Company's revenue concentration with respect to major payors as a percentage of the Company's total revenues:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Payor A | 15% | 20% | 15% | 21% |
| Payor B | 17% | 20% | 16% | 18% |
| Payor C | 14% | 11% | 13% | 10% |
| Payor E | 11% | \* | 11% | \* |

---

___________________________________________

\*Less than 10% of total revenues.

The following table provides the Company's concentration of credit risk with respect to major payors as a percentage of receivables, net:

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Payor B | \* | 11% |
| Payor C | 12% | 12% |
| Payor D | 14% | 13% |
| Payor E | 13% | 15% |

---

___________________________________________

\*Less than 10% of total receivables.

**NOTE 4. Marketable Securities and Fair Value Measurements**<br>

*Marketable Securities*

The following table summarizes the Company's marketable securities (in thousands):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Amortized Cost** | **Gross Unrealized Gains** | **Gross Unrealized Losses** | **Fair Value** | **Amortized Cost** | **Gross Unrealized Gains** | **Gross Unrealized Losses** | **Fair Value** |
| Corporate debt securities | $22296 | $11 | $— | $22307 | $110820 | $91 | $(204) | $110707 |
| U.S. Treasury notes | 116105 | 769 | (11) | 116863 | 101059 | 184 | (213) | 101030 |
|  | $138401 | $780 | $(11) | $139170 | $211879 | $275 | $(417) | $211737 |

---

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

For the three months ended September 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $3.8 million, of which $2.3 million was related to its marketable securities investments and $1.5 million was related to interest on cash and cash equivalent balances. For the three months ended September 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $4.6 million, of which $3.1 million was related to its marketable securities investments and $1.5 million was related to interest on cash and cash equivalent balances. For the nine months ended September 30, 2025, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $11.7 million, of which $8.0 million was related to its marketable securities investments and $3.7 million was related to interest on cash and cash equivalent balances. For the nine months ended September 30, 2024, the Company recognized total interest income (included in other income (expense), net in the condensed consolidated statements of operations) of $14.9 million, of which $10.3 million was related to its marketable securities investments and $4.6 million was related to interest on cash and cash equivalent balances.

The following table summarizes the Company's marketable securities maturity as of September 30, 2025 (in thousands):

---

| | | |
|:---|:---|:---|
| **Year** | **Amortized Cost** | **Fair Value** |
| 2025 | $23285 | $23285 |
| 2026 | 62571 | 62843 |
| 2027 | 27969 | 28218 |
| 2028 | 24576 | 24824 |
|  | $138401 | $139170 |

---

The following table summarizes the Company's marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of September 30, 2025 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Less Than 12 Months** | **Less Than 12 Months** | **12 Months or Greater** | **12 Months or Greater** |
| | **Fair Value** | **Gross Unrealized Losses** | **Fair Value** | **Gross Unrealized Losses** |
| U.S. Treasury notes | $12974 | $3 | $12820 | $8 |

---

The following table summarizes the Company's marketable securities with gross unrealized losses by security type aggregated by the length of time the investments have been in a continuous unrealized loss position as of December 31, 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Less Than 12 Months** | **Less Than 12 Months** | **12 Months or Greater** | **12 Months or Greater** |
| | **Fair Value** | **Gross Unrealized Losses** | **Fair Value** | **Gross Unrealized Losses** |
| Corporate debt securities | $— | $— | $73128 | $204 |
| U.S. Treasury notes | 25295 | 104 | 38787 | 109 |
|  | $25295 | $104 | $111915 | $313 |

---

The Company's unrealized losses from marketable securities as of September 30, 2025 and December 31, 2024 were caused primarily by interest rate increases. As of September 30, 2025, all of the Company's marketable securities carry an investment grade rating by nationally recognized statistical rating organizations. The Company does not intend to sell marketable securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. There was no allowance for credit losses on available-for-sale marketable securities at September 30, 2025 or December 31, 2024.

*Fair Value Measurements*

The Company's financial instruments consist of cash and cash equivalents, restricted cash and equivalents, marketable securities, receivables, other liabilities, accounts payable, certain accrued expenses, and borrowings which

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

consist of a term loan and a revolving credit facility. The carrying values of the financial instruments classified as current in the consolidated balance sheets approximate their fair values due to their short-term maturities. The fair values of the term loan and revolving credit facility approximate the carrying values because the interest rates on such borrowings approximate market rates as of the reporting date. Such borrowings are classified within Level 2 of the fair value hierarchy. During the three and nine months ended September 30, 2025 and 2024, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1—quoted prices for identical instruments in active markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2—quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3—fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The table below summarizes the Company's financial instruments measured at fair value on a recurring basis (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Level 1** | **Level 2** | **Level 3** | **Level 1** | **Level 2** | **Level 3** |
| **Marketable securities:** | | | | | | |
| Corporate debt securities | $— | $22307 | $— | $— | $110707 | $— |
| U.S. Treasury notes | 116863 |  |  | 101030 |  |  |
|  | $116863 | $22307 | $— | $101030 | $110707 | $— |

---

**NOTE 5. Other Assets**<br>

The following table summarizes the Company's other assets (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Loans to physician partners | $21116 | $63155 |
| Health plan deposits | 2077 | 2051 |
| Equity method investments<sup>(1)</sup> | 90469 | 61756 |
| Right-of-use lease assets | 3936 | 8783 |
| Other | 15084 | 15391 |
|  | $132682 | $151136 |

---

___________________________________________

(1)See Note 14 for additional discussion related to the Company's equity method investments.

*Loans to Physician Partners*

Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the Company's initial public offering. These loans mature between 2026 and 2031 with nominal interest compounding annually and no prepayment penalties. At September 30, 2025, $32.3 million of these loans were reclassed to Prepaid expenses and other current assets, net on the condensed consolidated balance sheet as the maturities were less than 12 months. Such loans are stated at the amount expected to be collected.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**NOTE 6. Medical Claims and Related Payables**<br>

Medical services expense represents costs incurred for medical services provided to members by physicians, hospitals and other ancillary providers for which the Company is financially responsible and are paid by payors with whom the Company has contracted. Medical services expenses are recognized in the period in which services are provided and include estimates of claims that have been incurred but have either not yet been received, processed, or paid and as such, not reported.

Such estimates are developed using actuarial methods commonly used by health insurance actuaries that include a number of factors and assumptions including medical service utilization trends, changes in membership, observed medical cost trends, historical claim payment patterns and other factors. Generally, for the most recent months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average PMPM medical costs incurred in prior months for which more complete claims data are available.

Each period, the Company re-examines previously established medical claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claims information becomes available, the Company adjusts its estimates and recognizes those changes in estimates in the period in which the change is identified. The difference between the estimated liability and the actual settlements of claims is recognized in the period the claims are settled. The Company's medical claims payable balance represents management's best estimate of its liability for unpaid medical costs as of September 30, 2025 and 2024. The Company uses judgment to determine the appropriate assumptions for developing the required estimates.

The following table presents the components of changes in medical claims and related payables (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,** | **September 30,** |
| | **2025** | **2024** |
| **Medical claims and related payables, beginning of the year** | $918395 | $723071 |
| Components of incurred costs related to: |  |  |
| &nbsp;&nbsp;&nbsp;Current year | 4301370 | 4291930 |
| &nbsp;&nbsp;&nbsp;Prior years | 35221 | 31922 |
|  | 4336591 | 4323852 |
| Claims paid related to: |  |  |
| &nbsp;&nbsp;&nbsp;Current year | (3267115) | (3158273) |
| &nbsp;&nbsp;&nbsp;Prior years | (957756) | (709936) |
|  | (4224871) | (3868209) |
| **Medical claims and related payables, end of the period** | $1030115 | $1178714 |

---

Medical claims and related payables also include $29.3 million and $13.3 million, as of September 30, 2025 and December 31, 2024, respectively, that is recoverable from other parties under risk sharing arrangements and is presented as prepaid expenses and other current assets, net in the condensed consolidated balance sheets.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**NOTE 7. Other Liabilities**<br>

The following table summarizes the Company's other liabilities (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Other long-term contingencies<sup>(1)</sup> | $35000 | $49000 |
| Lease liabilities, long-term | 2155 | 6599 |
| Equity method liabilities – CMS ACO Models<sup>(2)</sup> | 9786 | 12290 |
| Other | 3346 | 8232 |
|  | $50287 | $76121 |

---

__________________________________________

(1)Represents unasserted claims.

(2)See Note 14 for additional discussion related to the Company's equity method liabilities related to its CMS ACO Models investments.

**NOTE 8. Debt**<br>

On February 18, 2021, the Company executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the "Credit Agreement"), which includes: (i) a $100.0 million secured term loan facility (the "Secured Term Loan Facility," and together with the Secured Term Loan Facility, the "Credit Facility") and (ii) a $100.0 million senior secured revolving credit facility (the "Secured Revolving Facility") with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of the Company's indebtedness. The maturity date of the Credit Facility is February 18, 2026.

As of September 30, 2025, the Company had $35.0 million outstanding under the Secured Term Loan Facility and availability under the Secured Revolving Facility was $16.8 million, as the Company had outstanding letters of credit totaling $83.2 million. The standby letters of credit are automatically extended without amendment for one-year periods, unless the Company notifies the institution in advance of the expiration date that the letter will be terminated. No amounts have been drawn on the outstanding letters of credit as of September 30, 2025.

Effective with the Second Amendment to Credit Agreement on May 25, 2023, the Company transitioned to the Secured Overnight Financing Rate ("SOFR") as a benchmark interest rate used in the Credit Agreement. At the Company's option, borrowings under the Credit Facility can be either: (i) Term SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans, each as defined in the Credit Agreement. Daily Simple SOFR Rate Loans and Term SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, the Company pays a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. The Company must also pay customary letter of credit fees. As of September 30, 2025, the effective interest rate on the Secured Term Loan Facility was 8.272%.

The Credit Facility is guaranteed by certain of the Company's subsidiaries, including those identified as VIEs, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios. Failure to meet any of these covenants could result in an event of default under the Credit Agreement. If an event of default occurs, the lenders could elect to declare all amounts outstanding under the Credit Agreement to be immediately due and payable. As of September 30, 2025, the Company was in compliance with all covenants under the Credit Facility.

As of September 30, 2025, the Company had $9.5 million outstanding surety bonds related to health plan payor risk-bearing capital contributions.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**NOTE 9. Commitments and Contingencies**<br>

*Legal Proceedings*

From time to time, the Company is a party to, or has a significant relationship to, legal proceedings, lawsuits, and other claims that arise in the ordinary course of the Company's business. Except as described in this Note 9, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's business, prospects, financial condition, results of operations or cash flows. The Company's policy is to expense legal costs as they are incurred.

In February and March 2024, three class action lawsuits were filed and later consolidated as one matter captioned *In re agilon health, inc. Securities Litigation*, 1:24-cv-00297 (W.D. Tex.) (the "Consolidated Securities Matter"). The Consolidated Securities Matter names the Company and certain current and former members of the Company's executive team and Board of Directors as defendants, among others. The Consolidated Securities Matter generally asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended (the "Securities Act"), in connection with statements made between April 2021 and February 2024 in the Company's annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company's financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The Consolidated Securities Matter seeks compensatory damages, judgment interest, attorney's fees and costs, and other unspecified equitable and/or injunctive relief. The Company and other defendants filed motions to dismiss the complaint on November 8, 2024. On or about August 15, 2025, the Court issued an order on the motion to dismiss, dismissing some of the claims against the defendants and allowing others to proceed into the discovery phase of litigation. The Company intends to vigorously oppose the complaint, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stages of the litigation.

In May and October 2024, two putative stockholder derivative class action lawsuits were filed: (1) *Douglas v. Steven J. Sell et al.*, 1:24-cv-00531 (W.D. Tex.) and (2) *Bingham v. Steven J. Sell et al.*, 1:24-cv-01181 (W.D. Tex.) (the "Derivative Matters"). The Derivative Matters name the Company and certain current and former members of the Company's executive team and Board of Directors as defendants. The Derivative Matters generally assert claims under Sections 14(a) and 10(b) of the Exchange Act, as well as common law claims including breach of fiduciary duty, among others, in connection with statements made between April 2021 and February 2024 in the Company's annual and quarterly reports, investor presentations, and earnings releases related to, among other things, the Company's financial guidance, medical margin and Adjusted EBITDA results, growth strategy, and data management. The *Douglas* lawsuit also asserts claims under Section 20(a) of the Exchange Act in connection with the same allegations and seeks contribution under Section 11(f) of the Securities Act and Section 21D of the Exchange Act. The Derivative Matters seek compensatory damages, restitution, punitive damages, attorney's fees and costs, and other relief. The plaintiff in the *Douglas* action also seeks corporate governance reforms. The Derivative Matters were consolidated in November 2024 into *In Re agilon health, inc. Shareholder Derivative Litigation*, 1:24-cv-00531-DII. The Derivative Matters are currently stayed during the discovery period for the Consolidated Securities Matter. On or about September 18, 2025, a third putative stockholder derivative class action lawsuit was filed in federal court in Ohio, titled *Bushansky v. Steven J. Sell et al.*, 2:25-cv-01068 (S.D. Ohio). The allegations in this lawsuit are substantially the same as those asserted in the Derivative Matters. The Company plans to file a motion to transfer the matter to Texas to be consolidated with the pending Derivative Matters. The Company intends to vigorously oppose the Derivative Matters and the *Bushansky* lawsuit, but is unable to predict the outcome or estimate any ultimate individual or aggregate amount of monetary liability or financial impact due to the early stage of the litigation.

**NOTE 10. Common Stock**<br>

*Common Stock*

*2025*. During the three months ended September 30, 2025, the Company issued approximately 0.3 million shares of common stock primarily in connection with vesting of stock-based awards. During the nine months ended September 30, 2025, the Company issued approximately 2.4 million shares of common stock primarily in connection with vesting of stock-based awards.

*2024*. During the three months ended September 30, 2024, the Company issued approximately 0.5 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. During the nine months ended September 30, 2024, the Company issued approximately 3.6 million shares of common stock primarily in connection with exercises and vesting of stock-based awards. Additionally, during the nine months ended September 30, 2024, the

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

Company issued approximately 2.0 million shares of common stock to settle liabilities related to the exchange of common stock for reduced physician partner compensation percentage in certain ACO REACH entities.

**NOTE 11. Net Income (Loss) Per Common Share**<br>

Basic net income (loss) per common share ("EPS") is computed based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed based upon the weighted average number of common shares outstanding plus the impact of common shares issuable from the assumed conversion of stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on basic net income (loss) per share are included in diluted net income (loss) per share during the periods presented.

The following table illustrates the computation of basic and diluted EPS (in thousands, except per share amounts):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Numerator** |  |  |  |  |
| Income (loss) from continuing operations | $(110207) | $(116432) | $(216465) | $(143847) |
| Noncontrolling interests' share in (earnings) loss from continuing operations |  |  |  | (50) |
| Net income (loss) attributable to common stockholders before discontinued operations | (110207) | (116432) | (216465) | (143897) |
| Income (loss) from discontinued operations |  | (1183) | 14000 | (10464) |
| &nbsp;&nbsp;&nbsp;Net income (loss) attributable to common stockholders | $(110207) | $(117615) | $(202465) | $(154361) |
| **Denominator** |  |  |  |  |
| Weighted average shares outstanding – basic and diluted | 414465 | 411591 | 413751 | 410604 |
| **Net income (loss) per share attributable to common stockholders** |  |  |  |  |
| Net income (loss) per common share from continuing operations, basic and diluted | $(0.27) | $(0.29) | $(0.52) | $(0.35) |
| Net income (loss) per common share from discontinued operations, basic and diluted | $— | $— | $0.03 | $(0.03) |

---

The following table provides the potential shares of common stock that were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders because their effect would have been anti-dilutive (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,** | **September 30,** |
| | **2025** | **2024** |
| Stock options | 19,463 | 16,690 |
| Restricted stock units | 22,583 | 18,695 |

---

**NOTE 12. Goodwill and Amortizable Intangible Assets**<br>

As of both September 30, 2025 and December 31, 2024, the Company's goodwill balance was $24.1 million. There were no events or circumstances that warranted an interim impairment test for goodwill during the nine months ended September 30, 2025.

As of September 30, 2025 and December 31, 2024, the Company's gross carrying amount of amortizable intangible assets was $136.0 million and $123.8 million, respectively, with accumulated amortization of $60.7 million and

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

$51.0 million, respectively. For the three months ended September 30, 2025 and 2024, the Company recognized $3.6 million and $3.1 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations. For the nine months ended September 30, 2025 and 2024, the Company recognized $10.1 million and $9.1 million, respectively, in amortization expense, which is included in depreciation and amortization expense in the condensed consolidated statements of operations.

**NOTE 13. Supplemental Cash Flow Information**<br>

The following table provides supplemental cash flow information (in thousands):

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** |
| *Supplemental cash flow information:* |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid | $4774 | $3263 |
| &nbsp;&nbsp;&nbsp;Income taxes paid | 669 | 548 |
| *Supplemental disclosure of non-cash investing and financing activities:* |  |  |
| &nbsp;&nbsp;&nbsp;Right-of-use asset obtained in exchange for new operating lease liability | 1602 | 326 |
| &nbsp;&nbsp;&nbsp;Settlement of liabilities through issuance of stock |  | 15230 |

---

The following table summarizes cash, cash equivalents and restricted cash equivalents (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Cash and cash equivalents | $171684 | $188231 |
| Restricted cash and equivalents<sup>(1)</sup> |  | 5629 |
| &nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash equivalents | $171684 | $193860 |

---

___________________________________________

(1)Restricted cash and equivalents primarily consist of amounts used as collateral to secure letters of credit that the Company is required to maintain pursuant to contracts with payors.

**NOTE 14. Variable Interest Entities**<br>

*Consolidated Variable Interest Entities*

agilon health, inc.'s consolidated assets and liabilities as of September 30, 2025 and December 31, 2024 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to agilon health, inc.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

agilon health, inc.'s consolidated assets and liabilities include VIE assets and liabilities as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $59378 | $78650 |
| &nbsp;&nbsp;&nbsp;Restricted cash equivalents |  | 5627 |
| &nbsp;&nbsp;&nbsp;Receivables, net | 946571 | 1015753 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets, net | 33296 | 17725 |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 707 | 1255 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 54021 | 49406 |
| &nbsp;&nbsp;&nbsp;Other assets, net | 4330 | 4790 |
| **Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Medical claims and related payables | 1059398 | 931664 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 124634 | 199432 |
| &nbsp;&nbsp;&nbsp;Other liabilities | 1351 | 2270 |

---

*Risk-bearing Entities.* At September 30, 2025, the Company operates 33 wholly-owned risk-bearing entities ("RBEs") for the purpose of entering into risk-bearing contracts with payors. Each RBE's equity at risk is considered insufficient to finance its activities without additional support, and, therefore, each RBE is considered a VIE. The Company consolidates the RBEs as it has determined that it is the primary beneficiary because it has: (i) the ability to control the activities that most significantly impact the RBEs' economic performance; and (ii) the obligation to absorb losses or right to receive benefits that could potentially be significant to the RBEs. Specifically, the Company has the unilateral ability and authority, through the RBE governance and management agreements, to make significant decisions about strategic and operating activities of the RBEs, including negotiating and entering into risk-bearing contracts with payors, and approving the RBEs' annual operating budgets. The Company also has the obligation to fund losses of the RBEs and the right to receive a significant percentage of any financial surplus generated by the RBEs. The assets of the RBEs primarily consist of cash and cash equivalents, receivables, net, intangible assets, net, and other assets. Its obligations primarily consist of medical claims and related payables as well as operating expenses of the RBEs (accounts payable and accrued expenses), including incentive compensation obligations to the Company's physician partners. On February 18, 2021, the Company executed the Credit Facility, which is guaranteed by certain of the Company's VIEs. Assets generated by the RBEs (primarily from medical services revenues) may be used, in certain limited circumstances, to settle the Company's contractual debt obligations.

*Unconsolidated Variable Interest Entities*

As of September 30, 2025, the Company had 12 equity method investments (liabilities), including 10 wholly-owned CMS ACO Models entities discussed below, that were deemed to be VIEs. The Company has determined that the activities that most significantly impact the performance of these VIEs consist of the allocation of resources to and other decisions related to clinical activities and provider contracting decisions. Because the Company does not have the ability to control these activities due to another party's control of the VIEs' board of directors, the Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs. The Company provided support to assist its CMS ACO Models investments in obtaining surety bonds related to risk-bearing capital contributions to CMS. As of September 30, 2025 and December 31, 2024, the CMS ACO Models investments had $131.6 million and $65.2 million, respectively, of outstanding surety bonds. The Company's maximum loss exposure as a result of the Company's involvement with the unconsolidated VIEs cannot be quantified as the Company has the obligation to provide ongoing operational support to the unconsolidated VIEs, as needed.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

*Equity Method Investments*

The following table summarizes the Company's equity method investees (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Equity method investments - Other<sup>(1)</sup> | $9369 | $9365 |
| Equity method investments - CMS ACO Models<sup>(1)</sup> | 81100 | 52391 |
| Equity method liabilities - CMS ACO Models<sup>(2)</sup> | (9786) | (12290) |

---

___________________________________________

(1)Included in Other assets, net in the condensed consolidated balance sheets.

(2)Included in Other liabilities in the condensed consolidated balance sheets.

The Company is a partner in 10 wholly-owned CMS ACO Models investments in collaboration with 13 of its physician group partners operating in 12 geographies. The combined summarized operating results of the Company's CMS ACO Models investments are as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Medical services revenue | $458309 | $454410 | $1306580 | $1341484 |
| Medical services expense | (401473) | (413189) | (1155228) | (1218902) |
| Other medical expenses<sup>(1)</sup> | (33660) | (23817) | (87750) | (71490) |
| Income (loss) from operations<sup>(2)</sup> | 15321 | 3786 | 37930 | 24643 |
| Net income (loss)<sup>(3)</sup> | 13141 | 2014 | 31213 | 17566 |

---

___________________________________________

(1)The three months ended September 30, 2025 and 2024, includes physician incentive expenses of $26.6 million and $16.5 million, respectively. The nine months ended September 30, 2025 and 2024, includes physician incentive expenses of $63.2 million and $47.0 million, respectively.

(2)The three months ended September 30, 2025 and 2024, includes operating expenses for services provided by the Company of $3.7 million and $9.1 million, respectively. The nine months ended September 30, 2025 and 2024, includes operating expenses for services provided by the Company of $12.1 million and $11.7 million, respectively.

(3)Included in Income (loss) from equity method investments in the condensed consolidated statements of operations.

The combined summarized balance sheet of the Company's CMS ACO Models investments are as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Current assets | $307345 | $444963 |
| Noncurrent assets | 1894 | 1894 |
| Total assets | 309239 | 446857 |
| Current and total liabilities | 237926 | 406756 |

---

**NOTE 15. Discontinued Operations**<br>

Discontinued operations is a component of an entity that has either been disposed of or is deemed held-for-sale and, (i) the operations and cash flows of the component have been or will be eliminated from ongoing operations as a result of the disposal transaction, and (ii) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. On October 31, 2023, the Company completed the disposition of MDX Hawaii, Inc. and its related operations. The Company's decision to exit Hawaii and the Independent Practice Association line of business represented a strategic shift that had a major effect on its operations and financial results. As such, the Company's Hawaii operations are reflected in the condensed consolidated financial statements as discontinued operations for all periods presented.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

The results of discontinued operations are as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other medical expenses |  | 1420 |  | 1420 |
| &nbsp;&nbsp;&nbsp;General and administrative | $— | $(237) | $— | $281 |
| **Income (loss) from operations** |  | (1183) |  | (1701) |
| &nbsp;&nbsp;&nbsp;Adjustments on sale of assets, net |  |  | 14000 | (8763) |
| **Net income (loss) from discontinued operations attributable to common shares** | $— | $(1183) | $14000 | $(10464) |

---

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*All references in this report to "agilon," "the Company", "we," "us" or "our" mean agilon health, inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to "agilon health, inc." mean the parent company without its subsidiaries.*

**Cautionary Language Regarding Forward-Looking Statements**

Statements in this Quarterly Report on Form 10-Q (the "Report") that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Some of the forward-looking statements can be identified by the use of forward-looking terms such as "believes," "expects," "may," "will," "shall," "should," "would," "could," "seeks," "aims," "projects," "is optimistic," "intends," "plans," "estimates," "anticipates" or the negative versions of these words or other comparable terms. Forward-looking statements include, without limitation, all matters that are not historical facts. They appear in several places throughout this Report and include, without limitation, statements regarding our intentions, beliefs, assumptions or current expectations concerning, among other things, our financial position, results of operations, cash flows, prospects, and growth strategies.

Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Report, we caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of the market in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Report. In addition, even if our results of operations, financial condition, and cash flows, and the development of the market in which we operate, are consistent with the forward-looking statements contained in this Report, those results or developments may not be indicative of results or developments in subsequent periods. You are therefore cautioned not to place undue reliance on the forward-looking statements included in this report. A number of important factors, including, without limitation, the risks and uncertainties discussed under Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, could cause actual results and outcomes to differ materially from those reflected in the forward-looking statements. Furthermore, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Report. Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our history of net losses and the expectation that our expenses will increase in the future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to identify and develop successful new geographies, physician partners and payors, or execute upon our growth initiatives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• success in executing our operating strategies or achieving results consistent with our historical performance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• medical expenses incurred on behalf of our members may exceed revenues we receive;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain and secure additional contracts with Medicare Advantage ("MA") payors on favorable terms, if at all;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to grow new physician partner relationships sufficient to recover startup costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• availability of additional capital, on acceptable terms or at all, to support our business in the future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• significant reduction in our membership;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• transition to a Total Care Model may be challenging for physician partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• public health crises, such as COVID-19, could adversely affect us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• inaccuracy in estimates of our members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of restrictive clauses or exclusivity provisions in some of our contracts with physician partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to hire and retain qualified personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to realize the full value of our intangible assets;

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• security breaches, cybersecurity attacks, loss of data and other disruptions to our information systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to protect the confidentiality of our know-how and other proprietary and internally developed information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on our subsidiaries to perform and fund their operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our use of artificial intelligence and machine learning in our business and challenges with properly managing the development and use of these technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on a limited number of key payors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the limited terms of contracts with our payors and our ability to renew them upon expiration;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to navigate the changing healthcare payor market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on our payors, physician partners and other providers to operate our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to obtain accurate and complete diagnosis data;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on third-party software, data, infrastructure and bandwidth;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• consolidation and competition in the healthcare industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of changes to, and dependence on, federal government healthcare programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• regulation of the healthcare industry and our physician partners' ability to comply with such laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• federal and state investigations, audits and enforcement actions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• repayment obligations arising out of payor audits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• negative publicity regarding the managed healthcare industry generally;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our use, disclosure and processing of personally identifiable information, protected health information, and de-identified data;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to obtain or maintain an insurance license, a certificate of authority or an equivalent authorization;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in tax laws and regulations, or changes in related judgments or assumptions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our indebtedness and our potential to incur more debt;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our dependence on our subsidiaries for cash to fund all of our operations and expenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provisions in our governing documents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to achieve a return on investment depends on appreciation in the price of our common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• lawsuits not covered by insurance and securities class action litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• sustainability issues;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our stock price may be volatile;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks related to management transitions, including the search for a permanent Chief Executive Officer, and our ability to effectively manage leadership changes; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks related to other factors discussed under Part I, Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition, and results of operations and should be read in connection with the accompanying Condensed Consolidated Financial Statements and notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Report. We will discuss and provide our analysis in the following order:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Overview and Recent Developments

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Key Financial and Operating Metrics

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Key Components of Our Results of Operations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Results of Operations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP Financial Measures

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Liquidity and Capital Resources

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Critical Accounting Estimates

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Recent Accounting Pronouncements

**Overview and Recent Developments**

Our business is transforming healthcare by empowering the primary care physicians ("PCPs") to be the agent for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups, and a growing network of like-minded physicians, we believe we are poised to revolutionize healthcare for seniors across communities throughout the United States. We believe our purpose-built model provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by forming risk-bearing entities ("RBEs") within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners' attributed patients (or, global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.

Our business model is differentiated by its focus on existing community-based physician groups and is built around three key elements: (1) agilon's platform; (2) agilon's long-term physician partnership model; and (3) agilon's network. With our model, our goal is to remove the barriers that prevent community-based physicians from evolving to a Total Care Model, where the physician is empowered to manage health outcomes and the total healthcare needs of their attributed Medicare patients.

***Third Quarter 2025 Results:***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Medicare Advantage members of approximately 502,800 as of September 30, 2025 decreased 4% from September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* CMS ACO Models (defined below) attributed beneficiaries of approximately 115,300 as of September 30, 2025 decreased 13% from September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue of $1.4 billion decreased 1% from the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit of negative $68 million, compared to negative $64 million in the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Medical margin of negative $57 million, compared to negative $58 million in the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of $110 million, compared to net loss of $118 million in the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA loss of $91 million, compared to loss of $96 million in the third quarter of 2024.

***Year to Date 2025 Results as of September 30, 2025:***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue of $4.4 billion decreased 4% from nine months ended September 30, 2024.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit of negative $69 million, compared to positive $43 million in nine months ended September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Medical margin of $18 million, compared to $205 million in nine months ended September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of $202 million, compared to net loss of $154 million in nine months ended September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA loss of $154 million, compared to loss of $70 million in nine months ended September 30, 2024.

***Platform Membership Details***

Medicare Advantage members decreased 4% from September 30, 2024, which includes market exits during 2024, partially offset by contributions from new geographies and growth within geographies existing prior to 2025. Total members live on the agilon platform at September 30, 2025 include 502,800 Medicare Advantage members and 115,300 attributed CMS ACO Models beneficiaries.

Average Medicare Advantage membership was 510,400 during the third quarter of 2025.

***Payor Data Pipeline***

In the first quarter of 2025, we implemented a payor data pipeline (the "Model") and began onboarding certain payors onto the Model. The Model provides enhanced visibility into member risk profiles and risk adjustment factors by integrating and interpreting the data received from our payor partners. We are continuing the process of onboarding our payors onto the Model.

**Key Financial and Operating Metrics**

*All of our key metrics exclude historical results from our Hawaii operations (which are included as discontinued operations in our condensed consolidated financial statements).* 

We monitor the following key financial and operating metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following key metrics are useful in evaluating our business (dollars in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **As of and For the** | **As of and For the** | **As of and For the** | **As of and For the** | **As of and For the** | **As of and For the** |
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **% Change** | **2025** | **2024** | **% Change** |
| MA members | 502800 | 525200 | (4) | 502800 | 525200 | (4) |
| Medical services revenue | $1432437 | $1447697 | (1) | $4354355 | $4528471 | (4) |
| Gross profit (loss) | $(67646) | $(64167) | (5) | $(69351) | $43096 | (261) |
| Medical margin<sup>(1)</sup> | $(57042) | $(58253) | 2 | $17764 | $204619 | (91) |
| Platform support costs | $38652 | $42353 | (9) | $120313 | $129752 | (7) |
| Net income (loss) | $(110207) | $(117615) | 6 | $(202465) | $(154311) | (31) |
| Adjusted EBITDA<sup>(1)</sup> | $(91492) | $(96469) | 5 | $(154258) | $(70245) | (120) |

---

___________________________________________

(1)Medical margin and Adjusted EBITDA are non-GAAP financial measures. Gross profit (loss) is the most directly comparable financial measure calculated in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") to medical margin. Net income (loss) is the most directly comparable financial measure calculated in accordance with U.S. GAAP to Adjusted EBITDA. See "—Non-GAAP Financial Measures" below for additional information.

***Medicare Advantage Members***

Our MA members include all individuals enrolled in an MA plan that are attributed to the PCPs on our platform at the end of a given period.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

***Medical Services Revenue***

Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to per member per month ("PMPM") fees to provide a defined range of healthcare services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from the Centers for Medicare & Medicaid Services ("CMS"). We recognize capitation revenue over the period eligible members are entitled to receive healthcare services.

***Gross Profit (Loss)***

Gross profit (loss) represents the amount earned from total revenues less medical services expense and other medical expenses. Total revenues include medical services revenue and other operating revenue. The Company's costs of revenues consist of medical services expense and other medical expenses, which represents the costs that are directly related to providing the services that generate revenue.

The following table presents our gross profit (loss) (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Total revenues | $1435321 | $1450932 | $4363085 | $4538044 |
| Medical services expense | (1489479) | (1505950) | (4336591) | (4323852) |
| Other medical expenses<sup>(1)</sup> | (13488) | (9149) | (95845) | (171096) |
| Gross profit (loss) | $(67646) | $(64167) | $(69351) | $43096 |

---

___________________________________________

(1)Represents physician compensation expense related to surplus sharing and other care management expenses that help to create medical cost efficiency. Includes costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended September 30, 2025 and 2024, costs incurred in implementing geographies were $1.9 million and $1.4 million, respectively. For the nine months ended September 30, 2025 and 2024, costs incurred in implementing geographies were $0.9 million and $2.0 million, respectively.

***Medical Margin***

We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. Medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM.

See "—Non-GAAP Financial Measures" below for additional information regarding our use of medical margin and a reconciliation of gross profit (loss) to medical margin.

***Platform Support Costs***

Our platform support costs, which include regionally-based support personnel and other operating costs to support our geographies, are expected to decrease over time as a percentage of revenue as our physician partners add members and our revenue grows. Our operating expenses at the enterprise level include resources and technology to support payor contracting, clinical program development, quality, data management, finance, and legal and compliance functions.

The table below presents costs to support our live geographies and enterprise functions, which are included in general and administrative expenses (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Platform support costs | $38652 | $42353 | $120313 | $129752 |
| % of Revenue | 3% | 3% | 3% | 3% |

---

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

***Net Income (Loss) and Adjusted EBITDA***

Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA. We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis.

See "—Non-GAAP Financial Measures" below for additional information regarding our use of Adjusted EBITDA and a reconciliation of net income (loss) to Adjusted EBITDA.

**Key Components of Our Results of Operations**

***Revenues***

*Medical Services Revenue*

Our medical services revenue consists of capitation revenue under contracts with various payors. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of healthcare services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from CMS. We recognize capitation revenue over the period eligible members are entitled to receive healthcare services. In certain of our payor arrangements, we are also financially responsible for Medicare Part D pharmaceutical costs for prescriptions rendered to members.

Medical services revenue constitutes substantially all our total revenue for the three and nine months ended September 30, 2025 and 2024.

***Operating Expenses***

*Medical Services Expense* 

In each of our geographies, a network of physicians, hospitals, and other healthcare providers provide care to our members. Medical services expense represents costs incurred for medical services provided to our members. Our medical services expense trends primarily relate to changes in per visit costs incurred by our members, along with changes in health system and provider utilization of services. Medical services expenses are recognized in the period in which services are provided and include estimates of our obligations for medical services that have been rendered by third parties but for which claims have either not yet been received, processed, or paid.

*Other Medical Expenses*

Other medical expenses include: (i) partner physician compensation expense and (ii) other provider costs. Partner physician compensation expense represents obligations to our physician partners corresponding to a portion of the surplus generated in our geographies, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography. Physician payment obligations are reconciled quarterly, and settlement payments are typically issued to providers on an annual basis in arrears, with interim payments issued periodically. Other provider costs include payments to support physician-patient engagement, certain other medical costs, and other care management expenses that help to create medical cost efficiency. Other provider costs include costs incurred for geographies that are in implementation and are not yet generating revenue.

*General and Administrative* 

General and administrative expenses consist of market-based support personnel and other operating costs to support our geographies, personnel and other operating costs to support our enterprise functions, and investments to support development and expansion of our physician partners. Our enterprise functions include salaries and related expenses, stock-based compensation (including shares issued under partner physician group equity agreements), operational support expenses, technology infrastructure, finance, and legal, as well as other costs associated with the continued growth of our platform. For the purposes of calculating physician partner incentive expense, we allocate a portion of our enterprise general and administrative expenses to our geographies. General and administrative expenses also include severance and accruals for unasserted claims.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

*Depreciation and Amortization*

Depreciation and amortization expenses are associated with our property and equipment and acquired intangible assets. Depreciation includes expenses associated with computer equipment and software, furniture and fixtures, and leasehold improvements. Amortization primarily includes expenses associated with acquired intangible assets.

***Other Income (Expense)***

*Income (loss) from equity method investments*

Income (loss) from equity method investments consists primarily of income associated with our participation in the CMS the Accountable Care Organization Realizing Equity, Access, and Community Health ("ACO REACH") Model and Shared Savings Program ("MSSP") (collectively, "CMS ACO Models").

*Other Income (Expense), Net*

Other income (expense), net includes interest income, which consists primarily of interest earned on our cash and cash equivalents, restricted cash and equivalents, and marketable securities, including amortization/accretion of discount/premium.

*Interest Expense*

Interest expense consists primarily of interest expense associated with our outstanding debt, including amortization of debt discounts and issuance costs.

***Income Tax Benefit (Expense)***

We are subject to corporate U.S. federal, state, foreign, and local income taxation. Deferred tax assets are reduced by a valuation allowance to the extent management believes it is not more likely than not to be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. Management makes estimates and judgments about future taxable income based on assumptions that are consistent with our plans and estimates.

On July 4, 2025, the "One Big Beautiful Bill Act" was signed into law in the U.S., which contains a broad range of tax reform provisions. The One Big Beautiful Bill Act did not have a material impact to our effective tax rate for the nine months ended September 30, 2025; however, we will continue to monitor developments and evaluate any potential future impacts.

***Total Discontinued Operations***

Total discontinued operations primarily consist of the results of our former Hawaii operations. For certain of our divestiture transactions, we continue to be responsible for any liabilities arising from the business that were incurred prior to the closing date of such transaction, including any fines, penalties, and other sanctions, the payment of claims for medical services incurred prior to the effective date of each transaction, and other contingent liabilities that we currently believe are remote. For additional discussion, see Note 15 to the Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**Results of Operations**

The following table summarizes key components of our results of operations (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Revenues:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical services revenue | $1432437 | $1447697 | $4354355 | $4528471 |
| &nbsp;&nbsp;&nbsp;Other operating revenue | 2884 | 3235 | 8730 | 9573 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 1435321 | 1450932 | 4363085 | 4538044 |
| **Expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical services expense | 1489479 | 1505950 | 4336591 | 4323852 |
| &nbsp;&nbsp;&nbsp;Other medical expenses | 13488 | 9149 | 95845 | 171096 |
| &nbsp;&nbsp;&nbsp;General and administrative | 56198 | 63123 | 178435 | 209157 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 7430 | 6218 | 21625 | 17969 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 1566595 | 1584440 | 4632496 | 4722074 |
| **Income (loss) from operations** | (131274) | (133508) | (269411) | (184030) |
| **Other income (expense):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from equity method investments | 13133 | 2047 | 31217 | 17686 |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 9441 | 16061 | 26581 | 26794 |
| &nbsp;&nbsp;&nbsp;Interest expense | (1838) | (1622) | (4925) | (4603) |
| **Income (loss) before income taxes** | (110538) | (117022) | (216538) | (144153) |
| &nbsp;&nbsp;&nbsp;Income tax benefit (expense) | 331 | 590 | 73 | 306 |
| **Income (loss) from continuing operations** | (110207) | (116432) | (216465) | (143847) |
| **Discontinued operations:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) before gain (loss) on sales |  | (1183) |  | (1701) |
| &nbsp;&nbsp;&nbsp;Adjustments on sale of assets, net |  |  | 14000 | (8763) |
| **Total discontinued operations** |  | (1183) | 14000 | (10464) |
| **Net income (loss)** | (110207) | (117615) | (202465) | (154311) |
| &nbsp;&nbsp;Noncontrolling interests' share in (earnings) loss |  |  |  | (50) |
| **Net income (loss) attributable to common shares** | $(110207) | $(117615) | $(202465) | $(154361) |

---

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

The following table summarizes our results of operations as a percentage of total revenues:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Revenues:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical services revenue | 100% | 100% | 100% | 100% |
| &nbsp;&nbsp;&nbsp;Other operating revenue |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 100 | 100 | 100 | 100 |
| **Expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Medical services expense | 104 | 104 | 99 | 95 |
| &nbsp;&nbsp;&nbsp;Other medical expenses | 1 | 1 | 2 | 4 |
| &nbsp;&nbsp;&nbsp;General and administrative | 4 | 4 | 4 | 5 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 1 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 109 | 109 | 106 | 104 |
| **Income (loss) from operations** | (9) | (9) | (6) | (4) |
| **Other income (expense):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from equity method investments | 1 |  | 1 |  |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 1 | 1 | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Interest expense |  |  |  |  |
| **Income (loss) before income taxes** | (8) | (8) | (5) | (3) |
| &nbsp;&nbsp;&nbsp;Income tax benefit (expense) |  |  |  |  |
| **Income (loss) from continuing operations** | (8) | (8) | (5) | (3) |
| &nbsp;&nbsp;&nbsp;Discontinued operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) before gain (loss) on sales |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Gain (loss) on sales of assets, net |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Total discontinued operations |  |  |  |  |
| **Net income (loss)** | (8) | (8) | (5) | (3) |
| &nbsp;&nbsp;Noncontrolling interests' share in (earnings) loss |  |  |  |  |
| **Net income (loss) attributable to common shares** | (8)% | (8)% | (5)% | (3)% |

---

***Comparison of the Three and Nine Months Ended September 30, 2025 to the Three and Nine Months Ended September 30, 2024***

***Medical Services Revenue***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Medical services revenue | $1432437 | $1447697 | (1)% |
| *% of total revenues* | *100 %* | *100 %* |  |

---

Medical services revenue decreased by $15.3 million, or 1%, for the three months ended September 30, 2025 compared to the same period in 2024 primarily due to: (i) declines in average membership, which was attributable to partnership exits during 2024, and (ii) lower risk adjustment revenue, including unfavorable prior period development, as a

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

result of additional risk adjustment data received from payors. The decrease in medical services revenue was partially offset by new geographies that began to generate revenue in 2024 and growth in our existing geographies.

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Medical services revenue | $4354355 | $4528471 | (4)% |
| *% of total revenues* | *100 %* | *100 %* |  |

---

Medical services revenue decreased by $174.1 million, or 4%, for the nine months ended September 30, 2025 compared to the same period in 2024 primarily due to: (i) declines in average membership, which was attributable to partnership exits during 2024, and (ii) lower risk adjustment revenue, including unfavorable prior period development, as a result of additional risk adjustment data received from payors. The decrease in medical services revenue was partially offset by new geographies that began to generate revenue in 2024 and growth in our existing geographies.

***Medical Services Expense***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Medical services expense | $1489479 | $1505950 | (1)% |
| *% of total revenues* | *104 %* | *104 %* |  |

---

Medical services expense decreased by $16.5 million, or 1%, for the three months ended September 30, 2025 compared to the same period in 2024 due primarily to a decline in average membership of 5%, which was attributable to partnership exits during 2024, partially offset by an increase in average medical services expense per member of 4%, which was primarily due to the continued impact of elevated medical cost trends.

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Medical services expense | $4336591 | $4323852 | —% |
| *% of total revenues* | *99 %* | *95 %* |  |

---

Medical services expense increased by $12.7 million, or 0%, for the nine months ended September 30, 2025 compared to the same period in 2024 due primarily to an increase in average medical services expense per member of 5%, which was primarily due to the continued impact of elevated medical cost trends, partially offset by a decline in average membership of 4%, which was attributable to partnership exits during 2024.

***Other Medical Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Other medical expenses | $13488 | $9149 | 47% |
| *% of total revenues* | *1 %* | *1 %* |  |

---

Other medical expenses increased by $4.3 million, or 47%, for the three months ended September 30, 2025 compared to the same period in 2024. Partner physician incentive expense, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography, increased by $7.2 million to $(18.2) million in 2025 compared to $(25.4) million in the same period in 2024 primarily as a result of the losses generated in partnerships that were exited during 2024. Other provider costs decreased by $2.8 million to $31.7 million in 2025 compared to $34.5 million in the same period in 2024.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Other medical expenses | $95845 | $171096 | (44)% |
| *% of total revenues* | *2 %* | *4 %* |  |

---

Other medical expenses decreased by $75.3 million, or 44%, for the nine months ended September 30, 2025 compared to the same period in 2024. Partner physician incentive expense, which is a function of medical services revenues less the sum of medical services expenses, other provider costs and market operating costs, for the respective geography, decreased by $64.0 million to $(9.2) million in 2025 compared to $54.8 million in the same period in 2024 as a result of the losses generated in partnerships that were exited during 2024 and recent losses generated in certain of our geographies. Other provider costs decreased by $11.3 million to $105.0 million in 2025 compared to $116.3 million in the same period in 2024.

***General and Administrative***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| General and administrative | $56198 | $63123 | (11)% |
| *% of total revenues* | *4 %* | *4 %* |  |

---

General and administrative expenses decreased $6.9 million, or 11%, for the three months ended September 30, 2025 compared to the same period in 2024. Operating costs to support our live geographies and enterprise functions (platform support costs) decreased to $38.7 million in 2025, compared to $42.4 million in the same period in 2024. Investments to support geography entry decreased to $4.8 million in 2025, compared to $5.8 million in the same period in 2024 due to decreased costs associated with our geographies that are expected to become operational in subsequent calendar years and the expansion within existing geographies. Stock-based compensation expense decreased $5.8 million for the three months ended September 30, 2025, compared to the same period in 2024 primarily as the performance conditions on certain performance-based equity awards were deemed not probable, and thus the related costs were reversed. Costs incurred for severance and transaction-related costs increased by $3.6 million to $5.2 million in 2025 compared to $1.6 million in the same period in 2024 primarily due to the departure of our former Chief Executive Officer, as well as costs related to strategic changes in our workforce.

.

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| General and administrative | $178435 | $209157 | (15)% |
| *% of total revenues* | *4 %* | *5 %* |  |

---

General and administrative expenses decreased $30.7 million, or 15%, for the nine months ended September 30, 2025 compared to the same period in 2024. Operating costs to support our live geographies and enterprise functions (platform support costs) decreased to $120.3 million in 2025, compared to $129.8 million in the same period in 2024. Investments to support geography entry decreased to $15.6 million in 2025, compared to $21.2 million in the same period in 2024 due to decreased costs associated with our geographies that are expected to become operational in subsequent calendar years and the expansion within existing geographies. Stock-based compensation expense decreased $8.8 million for the nine months ended September 30, 2025, compared to the same period in 2024 primarily as the performance conditions on certain performance-based equity awards were deemed not probable, and thus the related costs were reversed. Costs incurred for severance and transaction-related costs decreased by $6.9 million to $2.9 million in 2025 compared to $9.8 million in the same period in 2024 primarily due to partnership exits during 2024, partially offset by the costs associated with the departure of our former Chief Executive Officer in 2025, as well as costs related to strategic changes in our workforce.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

***Income (loss) from equity method investments***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Income (loss) from equity method investments | $13133 | $2047 | 542% |
| % of total revenues | *1 %* | *— %* |  |

---

Income (loss) from equity method investments increased $11.1 million, or 542%, for the three months ended September 30, 2025 compared to the same period in 2024, primarily from our CMS ACO Models investments, consisting of higher medical margin and lower operating expenses, including the exit of under performing CMS ACO partners at the end of 2024.

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Income (loss) from equity method investments | $31217 | $17686 | 77% |
| % of total revenues | *1 %* | *— %* |  |

---

Income (loss) from equity method investments increased $13.5 million, or 77%, for the nine months ended September 30, 2025 compared to the same period in 2024, primarily from our CMS ACO Models investments, consisting of higher medical margin and lower operating expenses, including the exit of under performing CMS ACO partners at the end of 2024.

***Other income (expense), net***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Other income (expense), net | $9441 | $16061 | (41)% |
| *% of total revenues* | *1 %* | *1 %* |  |

---

Other income (expense), net decreased $6.6 million, or 41%, for the three months ended September 30, 2025 compared to the same period in 2024, primarily from additional income related to services rendered to our CMS ACO Models investments that was recognized in the third quarter of 2024.

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Other income (expense), net | $26581 | $26794 | (1)% |
| *% of total revenues* | *1 %* | *1 %* |  |

---

Other income (expense), net remained relatively flat for the nine months ended September 30, 2025 compared to the same period in 2024.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

***Total Discontinued Operations***

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Change** |
| *(dollars in thousands)* | **2025** | **2024** | $**%** |
| Total discontinued operations | $14000 | $(10464) | 234% |
| *% of total revenues* | *— %* | *— %* |  |

---

Total discontinued operations relates to the sale of our Hawaii operations in October 2023. Total discontinued operations for the nine months ended September 30, 2025 relates to the release of a contingent obligation from our Hawaii operations compared to losses from discontinued operations for the nine months ended September 30, 2024.

**Non-GAAP Financial Measures**

In addition to providing results that are determined in accordance with U.S. GAAP, we present medical margin and Adjusted EBITDA, which are non-GAAP financial measures.

We define medical margin as medical services revenue after medical services expense is deducted. Medical services expense represents costs incurred for medical services provided to our members. As our platform matures over time, we expect medical margin to increase in absolute dollars. However, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. We believe this metric provides insight into the economics of our capitation arrangements as it includes all medical services expense directly associated with our members' care.

We define Adjusted EBITDA as net income (loss) adjusted to exclude: (i) income (loss) from discontinued operations, net of income taxes, (ii) interest expense, (iii) income tax expense (benefit), (iv) depreciation and amortization, (v) stock-based compensation expense, (vi) severance and related costs, and (vii) certain other items that are not considered by us in the evaluation of ongoing operating performance. We reflect our share of Adjusted EBITDA for equity method investments by applying our actual ownership percentage for the period to the applicable reconciling items on an entity-by-entity basis.

Gross profit (loss) is the most directly comparable U.S. GAAP measure to medical margin. Net income (loss) is the most directly comparable U.S. GAAP measure to Adjusted EBITDA.

We believe medical margin and Adjusted EBITDA help identify underlying trends in our business and facilitate evaluation of period-to-period operating performance of our operations by eliminating items that are variable in nature and not considered by us in the evaluation of ongoing operating performance, allowing comparison of our recurring core business operating results over multiple periods. We also believe medical margin and Adjusted EBITDA provide useful information about our operating results, enhance the overall understanding of our past performance and future prospects, and allow for greater transparency with respect to key metrics we use for financial and operational decision-making. We believe medical margin and Adjusted EBITDA or similarly titled non-GAAP measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance. Other companies may calculate medical margin and Adjusted EBITDA or similarly titled non-GAAP measures differently from the way we calculate these metrics. As a result, our presentation of medical margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, limiting their usefulness as comparative measures.

Adjusted EBITDA is not considered a measure of financial performance under U.S. GAAP, and the items excluded therefrom are significant components in understanding and assessing our financial performance. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as an alternative to such U.S. GAAP measures as net income (loss), cash flows provided by or used in operating, investing, or financing activities or other financial statement data presented in our consolidated financial statements as an indicator of financial performance or liquidity. Some of these limitations are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect interest expense or the requirements necessary to service interest or principal payments on debt;

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect income tax expense (benefit) or the cash requirements to pay taxes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The expenses and other items that we exclude in our calculation of Adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from similarly titled non-GAAP financial measures.

The following table sets forth a reconciliation of gross profit (loss) to medical margin using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Gross profit (loss)<sup>(1)</sup> | $(67646) | $(64167) | $(69351) | $43096 |
| Other operating revenue | (2884) | (3235) | (8730) | (9573) |
| Other medical expenses | 13488 | 9149 | 95845 | 171096 |
| Medical margin | $(57042) | $(58253) | $17764 | $204619 |

---

___________________________________________

(1)Gross profit (loss) is defined as total revenues less medical services expense and other medical expenses.

The following table sets forth a reconciliation of net income (loss) to Adjusted EBITDA using data derived from our condensed consolidated financial statements for the periods indicated (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $(110207) | $(117615) | $(202465) | $(154311) |
| (Income) loss from discontinued operations, net of income taxes |  | 1183 | (14000) | 10464 |
| Interest expense | 1838 | 1622 | 4925 | 4603 |
| Income tax expense (benefit) | (331) | (590) | (73) | (306) |
| Depreciation and amortization | 7430 | 6218 | 21625 | 17969 |
| Severance and related costs | 4092 | 1453 | 4736 | 4736 |
| Stock-based compensation expense | 7498 | 13259 | 39599 | 48375 |
| EBITDA adjustments related to equity method investments<sup>(1)</sup> | 4969 | 9719 | 16178 | 15025 |
| Other<sup>(2)</sup> | (6781) | (11718) | (24783) | (16800) |
| Adjusted EBITDA | $(91492) | $(96469) | $(154258) | $(70245) |

---

___________________________________________

(1)Includes elimination of certain administrative services provided by agilon health, inc. to equity method investments.

(2)Includes interest income, transaction-related costs and elimination of certain administrative services provided by agilon health, inc. to equity method investments.

**Liquidity and Capital Resources**

We have historically financed our operations primarily through funds generated from our capitation arrangements with payors, issuances of equity securities, and borrowings under credit agreements. We generally invest any excess cash in money market accounts, which are classified as cash equivalents, and marketable securities. Our investment strategies are designed to provide safety and preservation of capital, and sufficient liquidity to meet the cash flow needs of our business

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

operations. As of September 30, 2025, we had cash and cash equivalents of $171.7 million and investments in marketable securities of $139.2 million.

We expect to continue to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments we intend to continue to make in expanding our business and additional general and administrative costs we expect to incur related to our operation as a public company. As a result, we may require additional capital resources in the future to execute strategic initiatives to grow our business.

Our primary uses of cash include payments for medical claims and other medical expenses, general and administrative expenses, costs associated with the development of new geographies and expansion of existing geographies, debt service, and capital expenditures. Final reconciliation and receipt of amounts due from payors are typically settled in arrears, following completion of the contractual program year.

Based on our planned operations, we believe that our existing cash and cash equivalents, investments in marketable securities, as well as available borrowing capacity under the Credit Facility (defined below), will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months, though we may require additional capital resources in the future. We have based these estimates on assumptions that may prove to be wrong and we could utilize our available capital resources sooner than we expect.

We may require additional financing in the future to fund working capital and pay our obligations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings and/or debt financings. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us, if at all. If adequate funds are not available on acceptable terms when needed, we may be required to significantly reduce operating expenses, which may have a material adverse effect on our business, financial condition, cash flows, and results of operations. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.

Our ability to pay dividends to holders of our common stock is significantly limited as a practical matter by our growth plans as well as the Credit Facility insofar as we may seek to pay dividends out of funds made available to us by agilon health management, inc. ("agilon management") or its subsidiaries because the Credit Facility restricts agilon management's ability to pay dividends or make loans to us. The borrower on the Credit Facility is agilon management, our wholly-owned subsidiary. The Credit Facility is guaranteed by certain of our subsidiaries, including those identified as variable interest entities, and contain customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.

***Cash Flows***

The following summary discussion of our cash flows is based on the condensed consolidated statements of cash flows. The following table sets forth changes in cash flows (dollars in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **Change** |
| Net cash provided by (used in) operating activities | $(85226) | $(74196) | $(11030) |
| Net cash provided by (used in) investing activities | 66027 | 116218 | (50191) |
| Net cash provided by (used in) financing activities | (2977) | (2561) | (416) |

---

*Net Cash Provided By (Used In) Operating Activities*

Net cash used in operating activities was $85.2 million for the nine months ended September 30, 2025 compared to $74.2 million for the nine months ended September 30, 2024. The increase in net cash used in operating activities was primarily as a result of the timing of settlements with payors. Our cash flow from operations is dependent upon the number of members on our platform, the timing of settlements with payors, and the level of operating and general and administrative expenses necessary to operate and grow our business, among other factors.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

*Net Cash Provided By (Used In) Investing Activities* 

Net cash provided by investing activities was $66.0 million for the nine months ended September 30, 2025 compared to $116.2 million for the nine months ended September 30, 2024. During the nine months ended September 30, 2025, we received net proceeds from the maturities of marketable securities and repayments of loans receivables of $100.4 million and made investments of $34.4 million primarily for the acquisition of intangible assets and property and equipment. During the nine months ended September 30, 2024, we received net proceeds from the maturities of marketable securities of $154.8 million and made investments of $38.6 million primarily for the acquisition of intangible assets and property and equipment.

*Net Cash Provided By (Used In) Financing Activities*

Net cash used in financing activities was $3.0 million for the nine months ended September 30, 2025, relating to equity issuances, compared to net cash used in financing activities of $2.6 million for the nine months ended September 30, 2024, related to repayments of debt.

***Debt Obligations***

On February 18, 2021, we executed a credit facility agreement (as amended by the First Amendment to Credit Agreement, dated as of March 1, 2021 and the Second Amendment to Credit Agreement, dated as of May 25, 2023, the "Credit Agreement," and together with the Secured Term Loan Facility, the "Credit Facility"), which includes: (i) a $100.0 million senior secured term loan (the "Secured Term Loan Facility") and (ii) a $100.0 million senior secured revolving credit facility (the "Secured Revolving Facility") with a capacity to issue standby letters of credit in certain circumstances up to a maximum of $100.0 million. Subject to specified conditions and receipt of commitments, the Secured Term Loan Facility may be expanded (or a new term loan facility, revolving credit facility or letter of credit facility added) by up to (i) $50.0 million plus (ii) an additional amount determined in accordance with a formula tied to repayment of certain of our indebtedness. The maturity date of the Credit Facility is February 18, 2026.

Effective with the Second Amendment to Credit Agreement on May 25, 2023, we transitioned to the Secured Overnight Financing Rate ("SOFR") as a benchmark interest rate used in the Credit Agreement. At our option, borrowings under the Credit Facility can be either: (i) Term SOFR Rate Loans, (ii) Daily Simple SOFR Rate Loans, or (iii) Base Rate Loans, each as defined in the Credit Agreement. Daily Simple SOFR Rate Loans and Term SOFR Rate Loans bear interest at a rate equal to the sum of 3.50% and the higher of (a) SOFR, as defined in the Credit Agreement, and (b) 0%. Base Rate Loans bear interest at a rate equal to the sum of 2.50% and the highest of: (a) 0.50% in excess of the overnight federal funds rate, (b) the prime rate established by the administrative agent from time to time, (c) the one-month SOFR rate (adjusted for maximum reserves) plus 1.00% and (d) 0%. Additionally, we pay a commitment fee on the unfunded Secured Revolving Facility amount of 0.375%. We must also pay customary letter of credit fees.

The Credit Facility contains customary covenants including, among other things, limitations on restricted payments including: (i) dividends and distributions from restricted subsidiaries, (ii) requirements of minimum financial ratios, and (iii) limitation on additional borrowings based on certain financial ratios.

For additional discussion on our debt obligations, see Note 8 to the Condensed Consolidated Financial Statements.

***Equity***

As of September 30, 2025, we had 414.6 million shares of common stock outstanding. See Note 10 to the Condensed Consolidated Financial Statements for additional information about our equity transactions.

**Critical Accounting Estimates**

Management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our historical experience, known trends and events, and various other assumptions that we believe are reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our condensed consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 in Part II, Item 7 "Management's Discussion and Analysis of Financial Conditions and Results of Operations - Critical Accounting Policies" and Note 2 to the Condensed Consolidated Financial Statements. There have been no significant changes to our critical accounting policies during 2025.

**Recent Accounting Pronouncements**

For the impact of new accounting standards, see Note 2 to the Condensed Consolidated Financial Statements.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates. We do not use derivative financial instruments in the normal course of business or for speculative or trading purposes.

Our exposures to market risk for changes in interest expense relate primarily to the Credit Facility. Indebtedness under the Credit Facility is floating rate debt and is carried at amortized cost. Therefore, fluctuations in interest rates will impact our consolidated financial statements. A rising interest rate environment will increase the amount of interest paid on this debt. A hypothetical 100 basis point change in interest rates would not have a material impact on our interest expense.

We held cash, cash equivalents, restricted cash and equivalents, and marketable securities of $310.9 million and $405.6 million as of September 30, 2025 and December 31, 2024, respectively, consisting of bank deposits, certificates of deposits, money market funds, U.S. Treasury notes, and corporate debt securities. Such interest-earning instruments carry a degree of interest rate risk. A hypothetical 100 basis point change in interest rates would not have a material impact on the fair value of our marketable securities. Declines in interest rates over time will reduce our investment income. The goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes.

**Item 4. Controls and Procedures** 

*Evaluation of Disclosure Controls and Procedures.* Our interim Principal Executive Officers (each a "PEO" and together, the "PEOs"), one of whom also serves as our Chief Financial Officer ("CFO"), with the assistance of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our PEOs and our CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's ("SEC") rules and forms and (2) accumulated and communicated to our management, including our PEOs and our CFO, as appropriate to allow timely decisions regarding required disclosure.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect every misstatement. An evaluation of effectiveness is subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may decrease over time.

*Changes in Internal Control Over Financial Reporting.* Under applicable SEC rules (Exchange Act Rules 13a-15(d) and 15d-15(d)), management is required to evaluate any change in internal control over financial reporting that occurred during each fiscal quarter that had materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no changes in our internal control over financial reporting that occurred during our most recently completed fiscal quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

See the "Legal Proceedings" section of Note 9 to the Condensed Consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 1.

**Item 1A. Risk Factors**

In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. There have been no material changes to the risk factors disclosed in the Form 10-K.

**Item 5. Other Information**

During the three months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as such terms are defined in Item 408 of Regulation S-K under the Act).

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**Item 6. Exhibits** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 3.1 | <u>[Amended and Restated By-laws of agilon health, inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed August 4, 2025).](https://www.sec.gov/Archives/edgar/data/1831097/000162828025037426/agl-20250630xexx31.htm)</u> |
| 10.1† | <u>[Separation Agreement](ex10-11.htm)[, dated as of](ex10-11.htm)[September](ex10-11.htm)[4](ex10-11.htm)[, 202](ex10-11.htm)[5](ex10-11.htm)[, by and between](ex10-11.htm)[Steven](ex10-11.htm)[Sell](ex10-11.htm)[and agilon health](ex10-11.htm)[, inc.†](ex10-11.htm)[\*](ex10-11.htm)</u> |
| 31.1 | <u>[Certification by Benjamin Shaker, agilon's interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).\*](agl-20250930xexx311.htm)</u> |
| 31.2 | <u>[Certification by Jeffrey Schwaneke, agilon's Principal Financial Officer and interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).\*](agl-20250930xexx312.htm)</u> |
| 32.1 | <u>[Certification by Benjamin Shaker, agilon's interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.\*\*](agl-20250930xexx321.htm)</u> |
| 32.2 | <u>[Certification by Jeffrey Schwaneke, agilon's Principal Financial Officer and interim Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.\*\*](agl-20250930xexx322.htm)</u> |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.\* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document.\* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document.\* |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document.\* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document.\* |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document).\* |

---

___________________________________________

\*Filed herewith.

\*\*Furnished herewith.

† &nbsp;&nbsp;&nbsp;&nbsp;Identifies each management contract or compensatory plan or arrangement.

------

<u>[**Table of Contents**](#if88d396afebb4b2997c2af615b3db7dc_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| Date: November 4, 2025 | agilon health, inc. |
| | (Registrant) |
| | /s/ JEFFREY SCHWANEKE |
| | Jeffrey Schwaneke |
| | *Chief Financial Officer and Member of the Office of the Chairman* |
| | *(Principal Financial Officer and Interim Principal Executive Officer)* |

---

## Exhibit 10.1

**CONFIDENTIAL**

**<u>SEPARATION AGREEMENT</u>**

This Separation Agreement (the "**<u>Agreement</u>**"), dated as of the date set forth on the signature page hereof, is entered into by and between Steven J. Sell (the "**<u>Executive</u>**") and agilon health, inc., a Delaware corporation (the "**<u>Company</u>**"). The Company and Executive are referred to herein individually as a "**<u>Party</u>**" and collectively as the "**<u>Parties</u>**."

**I.<u>RECITALS</u>**

WHEREAS, prior to the Separation Date (as defined below), Executive served as the Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the "**<u>Board</u>**") pursuant to that certain Employment Agreement between Executive and the Company, dated May 4, 2020 (the "**<u>Employment Agreement</u>**", with capitalized terms used in this Agreement but not defined in this Agreement have the meanings given in the Employment Agreement);

WHEREAS, effective as of July 29, 2025 (the "**<u>Separation Date</u>**"), Executive resigned from all roles with the Company and all of its subsidiaries and affiliates (the "**<u>Company Group</u>**"), and his resignation was a termination without Cause; and

WHEREAS, the Parties now intend and desire to specify, as well as settle and conclude, Executive's rights and obligations in connection with Executive's termination of employment with the Company Group.

NOW, THEREFORE, in consideration of the promises and the terms and provisions set forth herein, the mutual benefits to be gained by the performance thereof, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

**II.<u>AGREEMENT</u>**

1.**<u>Separation Date; Termination of Board Service</u>**. Executive's employment with the Company Group in all capacities, including Executive's service as a member of the Board, shall cease effective as of the close of business on the Separation Date. From and after the Separation Date, Executive agrees not to conduct business on behalf of the Company Group, including but not limited to speaking on behalf of the Company Group, entering into contracts on behalf of the Company Group and reporting to the offices of the Company Group. As required by Section 3(k) of the Employment Agreement, prior to or simultaneously with the execution and delivery of this Agreement, Executive is executing and delivering to the Company the resignation letter attached hereto as Exhibit A, and Executive shall execute promptly such other documents or instruments as the Company shall reasonably request in order to give effect to Executive's departure from the Company Group (provided that neither the entry into such resignation letter nor any such other action shall prejudice Executive's rights under this Agreement).

2.**<u>Severance Pay and Termination Benefits</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Severance Pay</u>. Pursuant to the Employment Agreement, and in consideration for, and subject to, Executive's execution and delivery of this Agreement, Executive

------

shall be entitled to severance pay of $1,687,500, consisting of (x) eighteen (18) months of Executive's base salary (equal to $1,125,000) (the "**<u>Base Salary Continuation</u>**") and (y) Executive's target bonus amount (equal to $562,500) (the "**<u>Target Bonus Amount</u>**"). The Base Salary Continuation shall be paid in eighteen (18) substantially equal monthly installments of $62,500, less applicable withholding taxes, over the eighteen (18) months following the Separation Date. The Target Bonus Amount shall be paid in twelve (12) substantially equal monthly installments of $46,875, less applicable withholding taxes, over the twelve (12) months following the Separation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Continued Medical, Dental and Vision Benefits</u>. Subject to Executive's timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("**<u>COBRA</u>**"), Executive will be entitled to receive direct payment or reimbursement of the COBRA cost of medical, dental and vision coverage (as elected by Executive) in excess of the active employee rate for twelve (12) months following the Separation Date, or such shorter period specified in Section 3(h) of the Employment Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Other Post-Employment Entitlements</u>. The Company confirms and agrees that, whether or not Executive enters into this Agreement, Executive shall be entitled to (1) the Base Termination Compensation, (2) the entitlements set forth in Section 21 of the Employment Agreement (entitled "**<u>D&O Insurance</u>**"), and (3) the entitlements set forth in Section 22 of the Employment Agreement (entitled "**<u>Indemnification</u>**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>No 2025 Annual Bonus</u>. Executive acknowledges having received payment of any annual bonus owed to him for the 2024 fiscal year of the Company and acknowledges and agrees that Executive will not be eligible for a payment of an annual bonus for the 2025 fiscal year of the Company, except as provided in Section 2(a) above.

3.**<u>Effect of Termination of Employment on Company Equity Awards</u>**. The effect of Executive's Separation Date on the outstanding Company equity awards held by Executive as of the Separation Date shall be as provided in the award agreements evidencing such equity awards, namely that: (1) all unvested restricted stock units, performance share units and stock options held by Executive as of the Separation Date shall be automatically forfeited and cease to be outstanding as of the Separation Date; and (2) all vested stock options held by Executive as of the Separation Date will be exercisable for ninety (90) days following the Separation Date, and, if not so exercised, will be automatically forfeited and cease to be outstanding at the expiration of such ninety (90) day period. No provision of this Agreement shall be construed to modify the treatment set forth in the applicable award agreements.

4.**<u>Consult Attorney</u>**. The Company hereby advises Executive in writing to consult with an attorney of Executive's choosing prior to entering into this Agreement, and Executive acknowledges having had the opportunity to do so.

5.**<u>Release of Claims by Executive</u>**. In consideration of the payments and benefits to which Executive is entitled hereunder, as of the Separation Date, Executive hereby waives and releases and forever discharges the Company and all of its subsidiaries, divisions, limited partnerships, affiliated corporations, successors and assigns; and the past and present directors, managers, officers, stockholders, partners, agents, employees, insurers, attorneys, and servants of all of the foregoing, each in his, her or its capacity as such, and

&nbsp;&nbsp;&nbsp;&nbsp;2

------

each of them separately and collectively (collectively, "**<u>Releasees</u>**"), from any and all existing claims, charges, complaints, liens, demands, causes of action, obligations, damages and liabilities, known or unknown, suspected or unsuspected, whether or not mature or ripe, that Executive ever had and now has against any Releasee, including without limitation arising out of or in any way related to Executive's employment with or separation from the Company, to any services performed for the Company, to any status, term or condition in such employment, or to any physical or mental harm or distress from such employment or non-employment or claim to any hire, rehire or future employment of any kind by the Company, all to the extent allowed by applicable law. This release of claims includes, but is not limited to, claims based on express or implied contract, compensation plans, covenants of good faith and fair dealing, wrongful discharge, claims for discrimination, harassment and retaliation, violation of public policy, tort or common law, whistleblower or retaliation claims; and claims for additional compensation or damages or attorneys' fees or claims under federal, state, and local laws, regulations and ordinances, including but not limited to Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Worker Adjustment and Retraining Notification Act ("**<u>WARN</u>**"), or equivalent state WARN Act, the Employee Retirement Income Security Act, and the Sarbanes-Oxley Act of 2002. Executive understands that this release of claims includes a release of all known and unknown claims through the date on which this release of claims becomes irrevocable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.Executive expressly waives any and all rights under Section 1542 of the Civil Code of the State of California and any like provision or principle of common law in any foreign jurisdiction. Section 1542 provides as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.**"A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor."**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.Notwithstanding the provisions of Section 1542, for the purpose of implementing a full and complete release and discharge, Executive expressly acknowledges that this Agreement is intended to include in its effect, without limitation, claims and causes of action which he does not know of or suspect to exist in Executive's favor at the time of execution of this Agreement and that this Agreement contemplates extinguishment of all such claims and causes of action. With full awareness and understanding of the above provisions, Executive hereby waives any rights Executive may have under Section 1542, as well as under any other statutes or common law principles of similar effect and expressly releases the Company and the other Releasees from claims which Executive does not presently know or suspect to exist at this time.

9.**<u>Limitation of Release</u>**. Notwithstanding the foregoing, this release of claims will not prohibit Executive from filing a charge of discrimination with the National Labor Relations Board, the Equal Employment Opportunity Commission or an equivalent state civil rights agency, but Executive agrees and understands that he is waiving his right to monetary compensation thereby if any such agency elects to pursue a claim on his behalf. Further, nothing in this release of claims shall be construed to waive any right that is not subject to waiver by private agreement under federal, state or local employment or other laws, such as claims for workers' compensation or unemployment benefits or any claims

&nbsp;&nbsp;&nbsp;&nbsp;3

------

that may arise after the date on which this release of claims becomes irrevocable. In addition, nothing in this release of claims will be construed to affect any of the following claims, all rights in respect of which are reserved:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Vested benefits under the general employee benefit plans of the Company Group (other than severance pay or termination benefits under any generally applicable severance policy);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any claim for unemployment compensation or workers' compensation administered by a state government to which Executive is presently or may become entitled;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Any right to payment under, or other performance of, this Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Executive's rights pursuant to the terms of the Indemnification Agreement between the Company and Executive dated as of December 4, 2024.

10.**<u>Acceptance and Revocability</u>**. Executive acknowledges that Executive has been given a period of at least twenty-one (21) days within which to consider the release of claims set forth in this Agreement. Executive may accept this release of claims at any time within this period of time by signing the release of claims and returning it to the Company. This release of claims shall not become effective or enforceable until seven (7) calendar days after Executive signs it. Executive may revoke Executive's acceptance of this release of claims at any time within that seven (7) calendar day period by sending written notice to the Company. Such notice must be received by the Company within the seven (7) calendar day period in order to be effective and, if so received, would void this Agreement and all of Executive's and the Company's rights and obligations hereunder, including the release of claims, for all purposes. The offer of severance pay made herein may be terminated by the Company if Executive does not enter into this Agreement within thirty (30) days following the Separation Date.

11.**<u>Non-Alienation</u>**. Executive shall not have any right to pledge, hypothecate, anticipate, or in any way create a lien upon any amounts due or payable under this Agreement, and no payments or benefits due hereunder shall be assignable in anticipation of payment either by voluntary or involuntary acts or by operation of law. So long as Executive lives, no person, other than the Parties hereto, shall have any rights under or interest in this Agreement or the subject matter hereof, except as expressly provided herein. If Executive shall die prior to full payment of the severance pay hereunder, the balance of the severance pay shall be paid in a lump sum to Executive's estate.

12.**<u>Cooperation; Reimbursement</u>**. Executive shall reasonably cooperate with the Company in connection with any claims or investigations relating to periods or matters while Executive was employed by the Company and as to which Executive has knowledge by virtue of Executive's employment with the Company. Executive shall be reimbursed for reasonable out-of-pocket expenses incurred in rendering such cooperation, subject to pre-approval of any expense that is in excess of $500.

13.**<u>Mutual Non-Disparagement</u>**. Subject to the Permitted Exceptions, Executive will not disparage the Company or any of its subsidiaries or affiliates, or any of the executive officers, directors, agents or employees or any of the foregoing persons or entities, or otherwise take any action which could reasonably be expected to adversely affect the personal or professional reputation of any of the foregoing persons or entities. Subject to the Permitted Exceptions, the Company will not (by press release of authorized statement

&nbsp;&nbsp;&nbsp;&nbsp;4

------

of a spokesperson), the members of the Board will not, and the Company will advise its executive officers to not, disparage Executive or his performance, or otherwise take any action which could reasonably be expected to adversely affect Executive's personal or professional reputation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Nothing in this Agreement shall prevent Executive or the Company from making or publishing any truthful statement (a) when required by law, subpoena or court order or at the request of an administrative agency or legislature, (b) in the course of any legal, arbitral, administrative, legislative or regulatory proceeding, (c) where a prohibition or limitation on such communication is unlawful, or (d) by one party in any dispute between the parties, in such truthful manner as may be responsive to a disparaging comment by the other party. In addition, nothing in this Agreement shall be construed to prohibit Executive from reporting possible violations of law or regulation to any governmental agency or regulatory body or making other disclosures that are protected under any law or regulation, or from filing a charge with or participating in any investigation or proceeding conducted by any governmental agency or regulatory body, in each case without prior notice to the Company or any of its directors, officers or employees. (The disclosures in this paragraph are the "**<u>Permitted Exceptions</u>**".)

14.**<u>Amendment of Agreement</u>**. This Agreement may not be modified or amended except by an instrument in writing signed by Executive and an authorized representative of the Company. Employee understands and agrees that any changes the Parties may make to this Agreement, whether material or immaterial, will not restart the time to consider this Agreement.

15.**<u>Waiver</u>**. No term or condition of this Agreement shall be deemed to have been waived, nor shall there be an estoppel against the enforcement of any provision of this Agreement, except by written instrument of the party charged with such waiver or estoppel.

16.**<u>Notices</u>**. Except as otherwise stated herein, for purposes of this Agreement, all notices or other communications hereunder shall be in writing and shall be given as provided in the Employment Agreement.

17.**<u>Severability and Interpretation</u>**. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in whole or part, such invalidity will not affect any other provision, and all other provisions will remain in full force and effect. The fact that counsel for any one of the Parties drafted this Agreement shall not be material to the construction of this Agreement.

18.**<u>Counterparts and Titles</u>**. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, and all of which together will constitute one document. The titles and headings preceding the text of the paragraphs and subparagraphs of this Agreement (including Appendices) have been inserted solely for convenience of reference and do not constitute a part of this Agreement or affect its meaning, interpretation or effect. This Agreement may be executed in counterparts and delivered electronically, including by email and .pdf file.

19.**<u>Governing Law</u>**. Section 15 of the Employment Agreement is incorporated by reference into this Agreement as if expressly set forth herein, including without limitation the waiver of jury trial set forth therein.

&nbsp;&nbsp;&nbsp;&nbsp;5

------

20.**<u>No Admission of Liability</u>**. Executive acknowledges, by entering into this Agreement, that the Company and the Releasees do not admit to the violation of any employment or labor law or any unlawful or tortious conduct or any other wrongdoing of any kind in connection with Executive or his employment.

21.**<u>Inadmissibility of Agreement</u>**. Neither this Agreement, nor any of its terms, nor any document, statement, proceeding or conduct related to this Agreement, nor any reports or accounts thereof, shall be construed as, offered or admitted in evidence as, received as, or deemed to be evidence for any purpose adverse to the Parties, including, without limitation, evidence of a presumption, concession, or admission by any of the Parties of any liability, fault, wrongdoing, omission, or damage.

22.**<u>Entire Agreement</u>**. This Agreement, the provisions of the Employment Agreement expressly incorporated herein and the award agreements evidencing equity awards held by Executive constitute the entire agreement of the Parties with respect to the subject matter hereof, and supersede all prior agreements, understandings, representations, negotiations, discussions or arrangements, either oral or written. For the avoidance of doubt, the restrictive covenants contained in agreements entered into by Executive and the Company Group prior to the Separation Date are hereby reaffirmed and shall remain binding on Executive and in full force and effect according to their terms following execution of this Agreement. None of the Parties have relied on any statements or representations that have been made by any other Party that are not set forth in this Agreement, and no Party is entitled to rely on any representation, agreement or obligation to disclose information that is not expressly stated in this Agreement.

23.**<u>Section 409A</u>**. This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the "**Section 409A**") and the interpretive guidance thereunder, and this Agreement shall be administered, interpreted and construed in a manner that does not result in the imposition of additional taxes, penalties or interest under Section 409A. The Company agrees to negotiate in good faith with Executive to make amendments to this Agreement, as both parties mutually agree are necessary or desirable to void the imposition of taxes, penalties or interest under Section 409A. If an amount to be paid under this Agreement is payable in two or more installments, each installment shall be treated as a separate payment for purposes of Section 409A. Neither the Company nor Executive will have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A. Any taxes or penalties assessed on Executive under Section 409A shall be the sole responsibility of Executive.

24.**<u>Third Party Beneficiaries and Binding Effect</u>**. Each of the Releasees who are not signatories to this Agreement are hereby agreed to be third party beneficiaries of this Agreement and shall be entitled to all rights, benefits, and protections of this Agreement, and shall further be entitled to enforce this Agreement and each of its terms. This Agreement shall be binding on the Parties hereto, together with their respective executors, administrators, successors, personal representatives, heirs, and assigns.

25.**<u>No Other Payments</u>**. Executive agrees that except for the payments provided in this Agreement, he is entitled to no other payments or compensation of any kind from the Company or any plan or policy of or agreement with the Company, including the Employment Agreement.

26.**<u>Further Assurances</u>**. Executive and the Company each agree to cooperate with the other to cause to be executed and delivered all such other instruments and documents, and to

&nbsp;&nbsp;&nbsp;&nbsp;6

------

take such other actions, as such other parties may reasonably request from time to time to effectuate the provisions and purposes of this Agreement (although no such action shall diminish Executive's rights under this Agreement).

*[Remainder of Page Intentionally Blank]*

&nbsp;&nbsp;&nbsp;&nbsp;7

------

**EACH SIGNATORY TO THIS AGREEMENT HAS ENTERED INTO THIS SEPARATION AGREEMENT AND COMPLETE RELEASE OF CLAIMS KNOWINGLY, VOLUNTARILY, FREELY AND WITHOUT DURESS AFTER HAVING CONSULTED WITH AN ATTORNEY OR ADVISOR OF THEIR CHOICE. EACH SIGNATORY AGREES THAT THEY HAVE FULLY READ AND UNDERSTAND THIS AGREEMENT (INCLUDING APPENDICES AND EXHIBITS) AND HAVE HAD A FULL AND FAIR OPPORTUNITY TO ASK ANY QUESTIONS THEY HAVE ABOUT THE AGREEMENT.**

*[Signature Pages Follow]*

&nbsp;&nbsp;&nbsp;&nbsp;8

------

IN WITNESS WHEREOF, the Parties have entered into this Agreement effective as of the date written below Executive's signature to this Agreement.

**EXECUTIVE: Steven J. Sell**<br>By: <u>/s/ STEVEN SELL</u> <br>Dated:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;9/4/2025&nbsp;&nbsp;&nbsp;&nbsp;</u>

*[Signature Pages Continue]*

&nbsp;&nbsp;&nbsp;&nbsp;9

------

IN WITNESS WHEREOF, the Parties have entered into this Agreement effective as of the date written below Executive's signature to this Agreement.

**AGILON HEALTH, INC.**

<br><u>/s/ MAT VARGHESE</u> <br>Name: Mat Varghese<br>Title: Chief People Officer

&nbsp;&nbsp;&nbsp;&nbsp;10

------

**CONFIDENTIAL**

**<u>Exhibit A<br></u><br> LETTER OF RESIGNATION**

[attached]

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Benjamin Shaker, certify that:

1. I have reviewed this quarterly report on Form 10-Q of agilon health, inc. for the period ended September 30, 2025;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: November 4, 2025 | By: | /s/ BENJAMIN SHAKER |
|  |  | Benjamin Shaker |
|  |  | *Chief Markets Officer and Member of the Office of the Chairman* |
|  |  | *(Interim Principal Executive Officer)* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jeffrey Schwaneke, certify that:

1. I have reviewed this quarterly report on Form 10-Q of agilon health, inc. for the period ended September 30, 2025;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

------

---

| | | |
|:---|:---|:---|
| Date: November 4, 2025 | By: | /s/ JEFFREY SCHWANEKE |
|  |  | Jeffrey Schwaneke |
|  |  | *Chief Financial Officer and Member of the Office of the Chairman* |
|  |  | *(Principal Financial Officer and Interim Principal Executive Officer)* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of agilon health, inc. (the "Company") on Form 10-Q for the period ending September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Benjamin Shaker, Chief Markets Officer and Member of the Office of the Chairman of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: November 4, 2025 | By: | /s/ BENJAMIN SHAKER |
|  |  | Benjamin Shaker |
|  |  | *Chief Markets Officer and Member of the Office of the Chairman* |
|  |  | *(Interim Principal Executive Officer)* |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of agilon health, inc. (the "Company") on Form 10-Q for the period ending September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jeffrey Schwaneke, Chief Financial Officer and Member of the Office of the Chairman of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: November 4, 2025 | By: | /s/ JEFFREY SCHWANEKE |
|  |  | Jeffrey Schwaneke |
|  |  | *Chief Financial Officer and Member of the Office of the Chairman* |
|  |  | *(Principal Financial Officer and Interim Principal Executive Officer)* |

---

<br>